

10080926

=> d his

(FILE 'HOME' ENTERED AT 18:46:48 ON 03 JUN 2003)

FILE 'REGISTRY' ENTERED AT 18:46:57 ON 03 JUN 2003

L1           STRUCTURE uploaded  
L2           4 S L1

FILE 'STNGUIDE' ENTERED AT 18:48:12 ON 03 JUN 2003

L3           FILE 'REGISTRY' ENTERED AT 18:48:59 ON 03 JUN 2003  
L4           STRUCTURE uploaded  
L4           2 S L3

FILE 'STNGUIDE' ENTERED AT 18:50:17 ON 03 JUN 2003

L5           FILE 'REGISTRY' ENTERED AT 18:52:33 ON 03 JUN 2003  
L6           STRUCTURE uploaded  
L6           9 S L5

FILE 'STNGUIDE' ENTERED AT 18:53:30 ON 03 JUN 2003

FILE 'STNGUIDE' ENTERED AT 18:57:42 ON 03 JUN 2003

L7           FILE 'REGISTRY' ENTERED AT 18:57:50 ON 03 JUN 2003  
L7           STRUCTURE uploaded  
L8           8 S L7

FILE 'STNGUIDE' ENTERED AT 19:01:11 ON 03 JUN 2003


L9           FILE 'REGISTRY' ENTERED AT 19:04:54 ON 03 JUN 2003  
L9           STRUCTURE uploaded  
L10          7 S L9  
L11          372 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:06:03 ON 03 JUN 2003

L12          78 S L11  
L13          10 S L11/THU  
L14          68 S L12 NOT L13  
L15          11 S L14 AND PATENT/DT  
L16          57 S L14 NOT L15

=> d l1

L1 HAS NO ANSWERS  
L1           STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l3


L3 HAS NO ANSWERS  
L3           STR

10080926




Structure attributes must be viewed using STN Express query preparation.

=> d 15  
L5 HAS NO ANSWERS  
L5 STR



Structure attributes must be viewed using STN Express query preparation.


=> d 17  
L7 HAS NO ANSWERS  
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 19  
L9 HAS NO ANSWERS  
L9 STR

10080926



G1 C,O,S,N

G2 C,H,O,S,N

G3 H,O,S,N,Cl,Br,F,I,Me,CH<sub>2</sub>,CH,CF<sub>3</sub>,CN

Structure attributes must be viewed using STN Express query preparation.

10080926

> d 1-10 bib abs hitstr

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:658121 CAPLUS  
DN 137:201294  
TI Preparation of pyrroloquinolines, pyridoquinolines, pyranoquinolines, and related tricyclic compounds as androgen receptor modulators  
IN Zhi, Lin; Van Oeveren, Cornelis Arjan; Chen, Jyun-Hung; Higuchi, Robert I.  
PA Ligand Pharmaceuticals Incorporated, USA  
SO PCT Int. Appl., 132 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066475	A2	20020829	WO 2002-IB537	20020223
	WO 2002066475	A3	20030123		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2002183346	A1	20021205	US 2002-80926	20020222
PRAI	US 2001-271189P	P	20010223		
OS	MARPAT	137:201294			
GI					

*this app'*

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title nonsteroidal tricyclic compds. I-VIII [wherein R1 = H, halo, NO<sub>2</sub>, OR<sub>12</sub>, SO<sub>0-2</sub>R<sub>12</sub>, NR<sub>12</sub>R<sub>13</sub>, or (un)substituted (halo)alkyl or heteroalkyl; R2 = H, halo, Me, CF<sub>3</sub>, CHF<sub>2</sub>, CF<sub>2</sub>Cl, CN, CF<sub>2</sub>OR<sub>12</sub>, CH<sub>2</sub>OR<sub>12</sub>, OR<sub>12</sub>, SO<sub>0-2</sub>R<sub>12</sub>, NR<sub>12</sub>R<sub>13</sub>, or (un)substituted (halo)alkyl, heteroalkyl, alkenyl, or alkynyl; R<sub>3</sub>-R<sub>8</sub> = independently H, halo, OR<sub>12</sub>, NR<sub>12</sub>R<sub>13</sub>, SO<sub>0-2</sub>R<sub>12</sub>, or (un)substituted (halo)alkyl, heteroalkyl, alkenyl, alkynyl, (hetero)aryl, or arylalkyl; or R<sub>3</sub>R<sub>5</sub> or R<sub>5</sub>R<sub>7</sub> = a bond; or C<sub>2</sub>R<sub>4</sub>R<sub>6</sub> or C<sub>2</sub>R<sub>6</sub>R<sub>8</sub> = (un)substituted carbocyclic or heterocyclic ring; R<sub>9</sub> and R<sub>10</sub> = independently H, halo, CN, OR<sub>12</sub>, NR<sub>12</sub>R<sub>13</sub>, Cm(R<sub>12</sub>)<sub>2</sub>mOR<sub>13</sub>, SO<sub>0-2</sub>R<sub>12</sub>, NR<sub>12</sub>COR<sub>13</sub>, or (un)substituted (halo)alkyl, heteroalkyl, or arylalkyl; R<sub>11</sub> = H, halo, CN, OR<sub>14</sub>, NR<sub>14</sub>R<sub>15</sub>, SO<sub>0-2</sub>R<sub>14</sub>, CH<sub>2</sub>R<sub>14</sub>, COR<sub>14</sub>, CO<sub>2</sub>R<sub>14</sub>, CONR<sub>13</sub>R<sub>14</sub>, or (un)substituted (halo)alkyl or heteroalkyl; R<sub>12</sub> and R<sub>13</sub> = independently H or (un)substituted (halo)alkyl, heteroalkyl, alkenyl, alkynyl, or (hetero)aryl; R<sub>14</sub> = H, COR<sub>15</sub>, CO<sub>2</sub>R<sub>15</sub>, CONR<sub>15</sub>R<sub>16</sub>, or (un)substituted (halo)alkyl, heteroalkyl, or (hetero)aryl; R<sub>15</sub> and R<sub>16</sub> = independently H or (un)substituted (halo)alkyl, or heteroalkyl; W = O or S; X = O, S, or NR<sub>14</sub>; Y = O, S, NR<sub>12</sub>, NOR<sub>12</sub>, or CR<sub>12</sub>R<sub>13</sub>; Z = O, S, or NR<sub>12</sub>; n = 0-2; m = 0-2; or pharmaceutically acceptable salts thereof] were prep'd. as modulators of androgen receptors. For example, cyclization of 6-hydrazino-4-trifluoromethylquinolin-2(1H)-one with 3-pentanone afforded the cis-5,6-dihydro-7H-pyrrolo[3,2-f]quinolin-2(1H)-one. Oxidn. with DDQ in CH<sub>2</sub>Cl<sub>2</sub> gave 6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-1H-pyrrolo[3,2-f]quinolin-2(1H)-one (IX). The latter exhibited 76% androgen receptor agonist efficacy with a potency (EC<sub>50</sub>) of 7.6 nM relative to dihydrotestosterone in co-transfection assays using CV-1 cells and displayed androgen receptor binding activity (IC<sub>50</sub>) of 1.7 nM. Pharmaceutical compns. and formulations of IX are also disclosed. I-VIII are useful for the treatment of acne, male-pattern baldness, impotence, sexual dysfunction, wasting disease, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers (no data). Pharmaceutical compns. and formulations of IX are also disclosed.

IT 453592-19-3P 453592-20-6P 453592-22-8P  
453592-30-8P 453592-41-1P 453592-46-6P  
453592-47-7P 453592-52-4P 453592-53-5P  
453592-54-6P 453592-55-7P 453592-56-8P  
453592-57-9P 453592-60-4P 453592-71-7P  
453592-72-8P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

10080926

PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(androgen receptor modulator; prepn. of pyrroloquinolines,  
pyridoquinolines, pyranoquinolines, and related tricyclic compds. as  
androgen receptor modulators)


RN 453592-19-3 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-9-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)




RN 453592-20-6 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-1-(1-methylethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453592-22-8 CAPLUS


CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-1-(4-methoxyphenyl)-2-methyl-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453592-30-8 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-1,2-dimethyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 453592-41-1 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-1,2,3,6-tetrahydro-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10080926




RN 453592-46-6 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 453592-47-7 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-(4-fluorophenyl)-1,2,3,6-tetrahydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




5<sup>b</sup>/S<sup>b</sup>

RN 453592-52-4 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-ethyl-1,2,3,6-tetrahydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-53-5 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-ethyl-1,2,3,6-tetrahydro-2-propyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)


10080926



RN 453592-54-6 CAPLUS  
CN 1H-Pyrrolo[3,2-f]quinoline-1-propanoic acid, 2,3,6,7-tetrahydro-2-methyl-7-oxo-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 453592-55-7 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-3,6-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 453592-56-8 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-1,2,3,6-tetrahydro-1-methyl-3-(2,2,2-trifluoroethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 453592-57-9 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-1,2-dimethyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-60-4 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)


10080926



RN 453592-71-7 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-3,6-dihydro-1-(hydroxymethyl)-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-72-8 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-(1-hydroxyethyl)-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 453592-21-7P 453592-23-9P 453592-42-2P  
453592-43-3P 453592-44-4P 453592-45-5P  
453592-48-8P 453592-49-9P 453592-50-2P  
453592-51-3P 453592-58-0P 453592-59-1P  
453592-61-5P 453592-62-6P 453592-67-1P  
453592-68-2P 453592-69-3P 453592-73-9P  
453592-74-0P 453592-75-1P 453592-76-2P  
453592-77-3P 453592-78-4P 453592-79-5P  
453593-25-4P 453593-26-5P 453593-30-1P  
453593-31-2P 453593-32-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
. (androgen receptor modulator; prepn. of pyrroloquinolines, pyridoquinolines, pyranooquinolines, and related tricyclic compds. as androgen receptor modulators)

RN 453592-21-7 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-1-(2-propenyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-23-9 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-9-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10080926




RN 453592-42-2 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-butyl-1,2,3,6-tetrahydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 453592-43-3 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-2-methyl-1-(4-nitrophenyl)-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 453592-44-4 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-[4-(dimethylamino)phenyl]-1,2,3,6-tetrahydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 453592-45-5 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-1-(4-methoxyphenyl)-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10080926




RN 453592-48-8 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-1-phenyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-49-9 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-1-(4-methoxyphenyl)-2-methyl-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 453592-50-2 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3-(2,2-dimethoxyethyl)-1,2,3,6-tetrahydro-1-(4-methoxyphenyl)-2-methyl-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 453592-51-3 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-2-methyl-1-(1-methylethyl)-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


10080926

Relative stereochemistry.




RN 453592-58-0 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 453592-59-1 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-61-5 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-ethyl-3,6-dihydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453592-62-6 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-ethyl-3,6-dihydro-2-propyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-67-1 CAPLUS


CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI)

10080926


(CA INDEX NAME)




RN 453592-68-2 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-(4-fluorophenyl)-3,6-dihydro-2-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453592-69-3 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-1-propanoic acid, 6,7-dihydro-2-methyl-7-oxo-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 453592-73-9 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-acetyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-74-0 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-1-carboxaldehyde, 6,7-dihydro-2-methyl-7-oxo-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10080926




RN 453592-75-1 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-[(acetyloxy)methyl]-2-ethyl-3,6-dihydro-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-76-2 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinoline-1-methanol, 7-(acetyloxy)-2-ethyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-77-3 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 2-ethyl-3,6-dihydro-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453592-78-4 CAPLUS


CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1-(ethoxymethyl)-2-ethyl-3,6-dihydro-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453592-79-5 CAPLUS

CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-2-(1-methoxyethyl)-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)


10080926




RN 453593-25-4 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 1,2,3,6-tetrahydro-2-(hydroxymethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453593-26-5 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3-ethyl-1,2,3,6-tetrahydro-2-(hydroxymethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453593-30-1 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453593-31-2 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxaldehyde, 6,7-dihydro-1-methyl-7-oxo-3-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 453593-32-3 CAPLUS  
CN 7H-Pyrrolo[3,2-f]quinolin-7-one, 3-(2,2-difluoroethenyl)-3,6-dihydro-1,2-dimethyl-9-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 2002:575080 CAPLUS

DN 137:149339

TI Anti-cancer 8-substituted quinolines and 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium

IN Denny, William Alexander; Wilson, William Robert; Ware, David Charles; Atwell, Graham John; Milbank, Jared Bruce John; Stevenson, Ralph James

PA Auckland Uniservices Limited, N. Z.

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002059122	A1	20020801	WO 2002-NZ5	20020122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI NZ 2001-509540 A 20010124

OS CASREACT 137:149339; MARPAT 137:149339

GI



AB This invention relates to heterocycles, e.g., 8-substituted quinolines and 2,3-dihydro-1H-pyrrolo[3,2-f]quinolines, and their metal complexes, and is particularly concerned using these compds. in the prepn. of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes, non-enzymic endogenous reducing agents, or by therapeutic ionizing radiation, in the treatment of cancer. Selected ligands and their cobalt(III) or chromium(III) complexes were evaluated for cytotoxicity in mammalian cell lines (AA8 Chinese hamster ovarian line, UV4 cell line as repair-defective ERCC-1 mutant, EMT6 murine mammary carcinoma line, and SKOV3 human ovarian cancer line). Thus, cobalt(III) cyclen complex I(ClO<sub>4</sub>)<sub>2</sub> (M1) was prep'd. and evaluated for cytotoxicity relative to the cytotoxic 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline free ligand. Complexation of the 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline in M1 resulted in considerable abrogation of cytotoxicity, indicating the utility of this approach in forming less toxic prodrugs of these cytotoxins. Complex M1 was also able to release the cytotoxic ligand in good yield when exposed to ionizing radiation in deoxygenated sodium formate buffer; a mechanism of activation of the M1 prodrug is briefly discussed. The invention also relates to the use of these heterocycles and the corresponding metal


10080926

complexes in the prepn. of medicaments and to compns. including the heterocycles or their metal complexes and to methods for prep. these compds.

IT 444565-29-1P 444565-30-4P 444565-31-5P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(for prepn. of 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium as anti-cancer prodrugs)

RN 444565-29-1 CAPLUS


CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-2,3-dihydro-3-[(5-methoxy-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 444565-30-4 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-2,3-dihydro-3-[(2E)-3-(4-methoxyphenyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 444565-31-5 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-2,3-dihydro-3-[(2E)-3-(3-hydroxy-4-methoxyphenyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 444565-27-9P 444565-28-0P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(intermediate; prepn. of 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium as anti-cancer prodrugs)

RN 444565-27-9 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]carbonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


10080926



RN 444565-28-0 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-3-[(2E)-3-[4-(dimethylamino)ethoxy]phenyl]-1-oxo-2-propenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 444565-08-6P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn., cytotoxicity, and complexation with cobalt or chromium as anti-cancer prodrugs)

RN 444565-08-6 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-(chloromethyl)-2,3-dihydro-3-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




IT 444565-16-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn., cytotoxicity, and complexation with cobalt or chromium as anti-cancer prodrugs)

RN 444565-16-6 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-amine, 1-(chloromethyl)-2,3-dihydro-3-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 2002:185120 CAPLUS

DN 136:232284

10080926

TI Preparation of pyrrolo[3,2-f]quinolin-2-ones as CDK4 inhibitors

IN Dickerson, Scott Howard; Drewry, David Harold

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 52 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020524	A1	20020314	WO 2001-US20703	20010628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001071611	A5	20020322	AU 2001-71611	20010628
	EP 1313732	A1	20030528	EP 2001-950642	20010628
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-230241P	P	20000901		
	WO 2001-US20703	W	20010628		
OS	MARPAT	136:232284			
GI					



I

AB Oxindole derivs., specifically pyrrolo[3,2-f]quinolin-2-ones I [R1 = (CR4R5)nNR2R3 and n = 1, 2; R2, R3 = H, alkyl, alkenyl, cycloalkyl, heterocyclyl, etc.; R4, R5 = H, alkyl, heterocyclyl, CH2Ph, Ph, etc.], which are useful as CDK4 inhibitors, are described herein. E.g., prepn. of 1-[{Z)-(4-dimethylaminomethylanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinoline-2-one by reaction of dimethylaminomethylidene-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one with 4-dimethylaminomethylaniline is described. Methods of using the same compds. in the treatment of hyperproliferative diseases was described.

IT 403713-22-4P 403713-23-5P 403713-24-6P

403713-26-8P 403713-27-9P 403713-28-0P

403713-29-1P 403713-30-4P 403713-32-6P

403713-34-8P 403713-36-0P 403713-38-2P

403713-40-6P 403713-42-8P 403713-43-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prep. of pyrrolo[3,2-f]quinolin-2-ones as CDK4 inhibitors)

RN 403713-22-4 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[[4-[(dimethylamino)methyl]phenyl]amin o]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 403713-23-5 CAPLUS

10080926

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[4-[(diethylamino)methyl]phenyl]amino]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-24-6 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[4-[(ethylmethylamino)methyl]phenyl]amino]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-26-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(methylpropylamino)methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-27-9 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(methyl(1-methylethyl)amino)methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 403713-28-0 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(methyl(2-methylpropyl)amino)methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

10080926


Double bond geometry as shown.



RN 403713-29-1 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[4-[(methylphenylmethyl)amino]methyl]phenyl]amino]methylene]-, (1Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 403713-30-4 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[4-[(2-hydroxyethyl)methylamino]methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-32-6 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[4-[(2-methoxyethyl)methylamino]methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 403713-34-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[4-[(4-morpholinylmethyl)phenyl]amino]methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10080926



RN 403713-36-0 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-38-2 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-40-6 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-42-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 403713-43-9 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[[methyl(1-methyl-4-piperidinyl)amino]methyl]phenyl]amino]methylen]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 2000:688216 CAPLUS

DN 133:266726

TI Preparation of 3-(anilinomethylene)oxindoles and analogs as protein tyrosine kinase and protein serine/threonine kinase inhibitors

IN Glennon, Kimberley Caroline; Kuyper, Lee Frederick; Lackey, Karen Elizabeth; McNutt, Robert Walton, Jr.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 189 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056710	A1	20000928	WO 2000-US5057	20000228
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	CH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1165514	A1	20020102	EP 2000-913643	20000228
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US	6350747	B1	20020226	US 2000-514528	20000228
JP	2002540097	T2	20021126	JP 2000-606572	20000228
US	6498176	B1	20021224	US 2001-914063	20010822
US	2002099071	A1	20020725	US 2001-966318	20010927
PRAI	GB 1999-4933	A	19990304		
	US 2000-514528	A3	20000228		
	WO 2000-US5057	W	20000228		
OS	MARPAT	133:266726			
GI					



**AB** The title compds. (I) [wherein X = N, CH, CCF<sub>3</sub>, or C(aliph.); Y, Z, A, and D = C or N, and the no. of N. ltoreq. 1; R1 = H, aliph., SH, hydroxy(aliph.), aryl(aliph.), cycloalkyl(aliph.), heterocyclyl(aliph.), (un)substituted NH<sub>2</sub>, CONH<sub>2</sub>, or SO<sub>2</sub>NH<sub>2</sub>, alkoxy carbonyl, halo, CN, or NO<sub>2</sub>; R2 = H, aliph., hydroxyimino aliph., alkoxy(carbonyl), hydroxyaliph., aryl(oxycarbonyl), heterocyclyl, (un)substituted CONH<sub>2</sub>, NH<sub>2</sub>, or SO<sub>2</sub>NH<sub>2</sub>, halo, OH, NO<sub>2</sub>, aliph. sulfonyl, etc.; or R1 and R2 are joined to form an (un)substituted fused heterocyclic ring; R3 = H, aliph., hydroxy(aliph.), (un)substituted NH<sub>2</sub>, CONH<sub>2</sub>, or SO<sub>2</sub>NH<sub>2</sub>, alkoxy, aryl(oxy), hydroxyaryl, (hydroxy)heterocyclyl, heterocyclyoxy, or halo; or R2 and R3 are joined to form an (un)substituted fused heterocyclic ring; R4 = SO<sub>3</sub>H, (aliph.)sulfonyl(aliph.), (un)substituted SO<sub>2</sub>NH<sub>2</sub>, NH<sub>2</sub>, CONH<sub>2</sub>, etc.; R5 = H; or R4 and R5 are joined to form an (un)substituted fused heterocyclic ring] were prepd. via std. synthetic methods and soln. phase library techniques as vascular endothelial growth factor receptor type 2 (VEGFR-2), cyclin dependent kinase 2 (CDK2), tyrosine kinase Tie-2 receptor, and colony-stimulating factor 1 receptor kinase (c-fms) inhibitors. For example, a mixt. of 8-dimethylaminomethylene-6,8-dihydro-1-thia-3,6-diaza-as-indacene-7-one (prepn. given) and 2-(4-aminophenyl)-3-methylpyrazolin-5-one in abs. EtOH was heated with stirring at 90.degree.C for 16 h to give (Z)-II (83%). In substrate phosphorylation assays, II inhibited VEGFR-2 and CDK2 with IC<sub>50</sub> values of 1-10 .mu.M and 11-50 .mu.M, resp. I are useful as therapeutic agents in disease states alleviated by the inhibition or antagonism of protein kinase activated signalling pathways in general, and in particular in the pathol. processes which involve aberrant cellular proliferation, such as tumor growth, restenosis, atherosclerosis, and thrombosis. I are particularly useful for suppressing tumor growth by inhibiting tumor-related angiogenesis.

**IT**


297754-16-6P, 1-[(3-Methoxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-17-7P, 3-[[2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]benzonitrile  
 297754-18-8P, 1-[(4-Toluidinomethylidene)-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-19-9P, 1-[(4-Methoxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one  
 297754-31-5P, 1-[(4-(4-Morpholinyl)anilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-32-6P  
 297754-33-7P, N-[4-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]acetamide 297754-34-8P  
 297754-35-9P, 4-[[2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]benzamide 297754-36-0P 297754-64-4P  
 , 1-[(4-Phenoxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-65-5P 297754-68-8P, Methyl  
 4-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenoxy]benzoate 297754-69-9P, Methyl  
 3-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenoxy]benzoate 297754-72-4P,  
 3-Ethyl-3-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]-2,6-piperidinedione 297754-75-7P,  
 1-[(4-Benzoylanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-77-9P, 1-[(3-(Hydroxymethyl)anilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297754-80-4P  
 297754-81-5P, 3-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]benzamide 297754-82-6P,  
 4-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]benzonitrile 297754-83-7P, Methyl  
 4-[(2-Oxo-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]benzoate 297754-87-1P, 1-[(4-[[2-

10080926

(Diethylamino)ethyl]sulfonyl]anilino)methylidene]-1H-pyrrolo[3,2-f]quinolin-2(3H)-one 297756-51-5P, 1-[(Z)-(3-Methoxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297756-52-6P 297756-53-7P 297756-54-8P  
297756-62-8P 297756-63-9P 297756-64-0P  
297756-65-1P 297756-66-2P 297756-67-3P,  
1-[(Z)-(4-Hydroxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297756-91-3P, 1-[(Z)-(4-Phenoxyanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297756-92-4P, 1-[(Z)-[4-(Benzoyloxy)anilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297756-93-5P  
297756-94-6P 297756-95-7P 297756-96-8P,  
1-[(Z)-(4-Benzoylanilino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-f]quinolin-2-one 297756-97-9P 297756-98-0P  
297756-99-1P 297757-00-7P 297757-01-8P  
297757-02-9P 297757-04-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of anilinomethylene oxindolones and analogs as protein tyrosine kinase and protein serine/threonine kinase inhibitors by alkylation and amination of oxindolones via std. or soln. phase library methods)


RN 297754-16-6 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(3-methoxyphenyl)amino)methylene]- (9CI) (CA INDEX NAME)



RN 297754-17-7 CAPLUS


CN Benzonitrile, 3-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]- (9CI) (CA INDEX NAME)




RN 297754-18-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-methylphenyl)amino)methylene]- (9CI) (CA INDEX NAME)


10080926



RN 297754-19-9 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-methoxyphenyl)amino]methylene] - (9CI) (CA INDEX NAME)




RN 297754-31-5 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(4-morpholinyl)phenyl]amino]methylene] - (9CI) (CA INDEX NAME)




RN 297754-32-6 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(4-pyridinylamino)phenyl]amino]methylene] - (9CI) (CA INDEX NAME)


10080926



RN 297754-33-7 CAPLUS  
CN Acetamide, N-[4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 297754-34-8 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(2-hydroxyethyl)phenyl]amino]methylene]- (9CI) (CA INDEX NAME)




RN 297754-35-9 CAPLUS  
CN Benzamide, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]- (9CI) (CA INDEX NAME)


10080926



RN 297754-36-0 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-hydroxyphenyl)amino]methylene- (9CI) (CA INDEX NAME)




RN 297754-64-4 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-phenoxyphenyl)amino]methylene- (9CI) (CA INDEX NAME)



RN 297754-65-5 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-(phenylmethoxy)phenyl)amino]methylene- (9CI) (CA INDEX NAME)


10080926




RN 297754-68-8 CAPLUS

CN Benzoic acid, 4-[4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 297754-69-9 CAPLUS


CN Benzoic acid, 3-[4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

10080926




RN 297754-72-4 CAPLUS

CN 2,6-Piperidinedione, 3-[4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]-3-ethyl- (9CI) (CA INDEX NAME)



RN 297754-75-7 CAPLUS


CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[(4-benzoylphenyl)amino]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 297754-77-9 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[3-(hydroxymethyl)phenyl]amino]methylene]- (9CI) (CA INDEX NAME)


10080926



RN 297754-80-4 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[4-(2,3-dihydro-5-methyl-3-oxo-1H-pyrazol-1-yl)phenyl]amino]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 297754-81-5 CAPLUS  
CN Benzamide, 3-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino- (9CI) (CA INDEX NAME)




RN 297754-82-6 CAPLUS  
CN Benzonitrile, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino- (9CI) (CA INDEX NAME)


10080926



RN 297754-83-7 CAPLUS  
CN Benzoic acid, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 297754-87-1 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[[4-[[2-(diethylamino)ethyl]sulfonyl]phenyl]amino]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 297756-51-5 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(3-methoxyphenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10080926



RN 297756-52-6 CAPLUS

CN Benzonitrile, 3-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-53-7 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-methylphenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-54-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-methoxyphenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 297756-62-8 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(4-morpholinyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10080926




RN 297756-63-9 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(4-pyridinylmethyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 297756-64-0 CAPLUS  
CN Acetamide, N-[4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 297756-65-1 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-(2-hydroxyethyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-66-2 CAPLUS  
CN Benzamide, 4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10080926



RN 297756-67-3 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-hydroxyphenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-91-3 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-phenoxyphenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-92-4 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[(4-(phenylmethoxy)phenyl)amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 297756-93-5 CAPLUS

CN Benzoic acid, 4-[[((Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10080926




RN 297756-94-6 CAPLUS  
CN Benzoic acid, 3-[4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 297756-95-7 CAPLUS  
CN 2,6-Piperidinedione, 3-[4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino]phenyl]-3-ethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 297756-96-8 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[(4-benzoylphenyl)amino]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297756-97-9 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[[3-(hydroxymethyl)phenyl]amino]methylene]-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10080926



RN 297756-98-0 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[4-(2,3-dihydro-5-methyl-3-oxo-1H-pyrazol-1-yl)phenyl]amino]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 297756-99-1 CAPLUS


CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1,3-dihydro-1-[[4-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl]amino]methylene]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A




10080926

RN 297757-00-7 CAPLUS

CN Benzamide, 3-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297757-01-8 CAPLUS

CN Benzonitrile, 4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297757-02-9 CAPLUS

CN Benzoic acid, 4-[(Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)methyl]amino-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 297757-04-1 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[[4-[[2-(diethylamino)ethyl]sulfonyl]phenyl]amino]methylene]-1,3-dihydro-, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 2000:454835 CAPLUS

10080926

DN 133:171758

TI Pyrrolo-quinoline derivatives as potential antineoplastic drugs

AU Ferlin, M. G.; Gatto, B.; Chiarelotto, G.; Palumbo, M.

CS Department of Pharmaceutical Sciences, University of Padova, Padua, 35131, Italy

SO Bioorganic & Medicinal Chemistry (2000), 8(6), 1415-1422

CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

AB Some novel pyrrolo-quinoline derivs. have been synthesized as potential antineoplastic agents. They contain an angular arom. tricyclic or tetracyclic system, to which the methanesulfon-anisidine side chain typical of amsacrine as such, or lacking the m-methoxy substituent, is connected. A Me group can be present at position 7 of the pyrrolo-quinoline ring. The novel compds. exhibit interesting cell growth inhibitory properties when tested against the NCI panel of cell lines, in particular those obtained from solid tumors like CNS-, melanoma- and prostate-derived cells. The mechanism of cytotoxic action does not seem to be related to topoisomerase II poisoning ability. Most active proved to be compd. 4a, which lacks both Me and methoxy substituents, followed by 5a, having the methoxy group only. Biol. activity is less pronounced in the tetracyclic family of derivs. 6 and 7.

IT 288570-10-5P 288570-11-6P 288570-12-7P


288570-13-8P 288570-14-9P 288570-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrrolo-quinoline derivs. as potential antineoplastic drugs)


RN 288570-10-5 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline, 9-chloro- (9CI) (CA INDEX NAME)




RN 288570-11-6 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline, 9-chloro-7-methyl- (9CI) (CA INDEX NAME)



RN 288570-12-7 CAPLUS

CN Methanesulfonamide, N-[4-(3H-pyrrolo[3,2-f]quinolin-9-ylamino)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 288570-13-8 CAPLUS

CN Methanesulfonamide, N-[4-[(7-methyl-3H-pyrrolo[3,2-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10080926




✓

● HCl

RN 288570-14-9 CAPLUS

CN Methanesulfonamide, N-[3-methoxy-4-(3H-pyrrolo[3,2-f]quinolin-9-ylamino)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




✓

● HCl

RN 288570-15-0 CAPLUS

CN Methanesulfonamide, N-[3-methoxy-4-[(7-methyl-3H-pyrrolo[3,2-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



✓

● HCl

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

AN 1999:736646 CAPLUS

DN 131:336827

TI Novel substituted cyclic compounds, particularly N-[2-(1-naphthyl)ethyl]acetamides and analogs with melatonin receptor activity, preparation method, and pharmaceutical compositions containing them

IN Lesieur, Daniel; Klupsch, Frederique; Guillaumet, Gerald; Viaud, Marie-Claude; Langlois, Michel; Bennejean, Caroline; Renard, Pierre; Delagrange, Philippe

PA Adir Et Compagnie, Fr.

SO PCT Int. Appl., 167 pp.  
CODEN: PIXD2

DT Patent


LA French

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 9958495	A1	19991118	WO 1999-FR1100	19990510
W: AU, BR, CA, CN, HU, JP, NO, NZ, PL, US, ZA				


10080926

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE  
FR 2778662 A1 19991119 FR 1998-5957 19980512  
FR 2778662 B1 20000616  
CA 2331870 AA 19991118 CA 1999-2331870 19990510  
AU 9936103 A1 19991129 AU 1999-36103 19990510  
AU 748567 B2 20020606  
EP 1077927 A1 20010228 EP 1999-918036 19990510  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI  
BR 9911771 A 20011002 BR 1999-11771 19990510  
JP 2002514619 T2 20020521 JP 2000-548299 19990510  
NZ 507691 A 20020531 NZ 1999-507691 19990510  
NO 2000005714 A 20001113 NO 2000-5714 20001113  
PRAI FR 1998-5957 A 19980512  
WO 1999-FR1100 W 19990510  
OS MARPAT 131:336827  
GI



II

- AB The invention concerns compds. of formula R-A-R' [I; wherein: A = various bi- and tricyclic carbo- and heterocyclic systems; R = SH and various derivs. such as thioethers, sulfoxides, and sulfones, (un)substituted amino, or may form ring with A; R' = (CH<sub>2</sub>)<sub>n</sub>R2 where n = 0-4 and R2 = various amide-contg. groups] and their stereoisomers and salts. The compds. are ligands of melatonin receptors, and are useful for prep. medicines for treating a variety of melatonin-related conditions, such as seasonal depression, anxiety, sleep and eating disorders, etc. For instance, title compd. II was prep'd. in 7 steps: (1) acylation of thioanisole with succinic anhydride to give 4-[4-(methylthio)phenyl]-4-oxobutanoic acid; (2) redn. of oxo with Et<sub>3</sub>SiH; (3) cyclization to form a 1-naphthalenone; (4) Wittig reaction with di-Et cyanomethylphosphonate; (5) dehydrogenation with sulfur at 230.degree.; (6) redn. of the nitrile with BH<sub>3</sub>.THF; and (7) N-acetylation of the resulting amine with AcCl. Compds. I showed little or no oral toxicity in mice, and bound strongly to mt1 and MT2 receptors in vitro, with IC<sub>50</sub> values < 10 μM. The compds. also showed circadian rhythm, anxiolytic, and vasoconstrictor/vasodilator activities in rats or in vitro.
- IT 250162-28-8P, N-[(2-Benzyl-6-ethyl-6,7-dihydrothieno[3,2-f]quinolin-1-yl)methyl]acetamide  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (target compd.; prepn. of bicyclic arom. and heteroarom. compds. as melatonin receptor ligands)
- RN 250162-28-8 CAPLUS
- CN Acetamide, N-[(6-ethyl-6,7-dihydro-2-(phenylmethyl)thieno[3,2-f]quinolin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:222914 CAPLUS  
DN 130:267341  
TI Preparation of oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors.

10080926

IN Davis, Stephen Thomas; Dickerson, Scott Howard; Frye, Stephen Vernon;  
 Harris, Philip Anthony; Hunter, Robert Neil, III; Kuyper, Lee Frederick;  
 Lackey, Kary Elizabeth; Luzzio, Michael Joseph; Veal, James Marvin;

Walker, Duncan Herrick

PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 133 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915500	A1	19990401	WO 1998-EP5559	19980903
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2302572	AA	19990401	CA 1998-2302572	19980903
	AU 9897407	A1	19990412	AU 1998-97407	19980903
	AU 747506	B2	20020516		
	ZA 9808078	A	20000322	ZA 1998-8078	19980903
	EP 1009738	A1	20000621	EP 1998-951342	19980903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9812048	A	20000926	BR 1998-12048	19980903
	EE 200000117	A	20001215	EE 2000-200000117	19980903
	JP 2001517652	T2	20011009	JP 2000-512809	19980903
	US 6369086	B1	20020409	US 1999-262351	19990304
	MX 200002254	A	20001030	MX 2000-2254	20000303
	US 6387919	B1	20020514	US 2000-486960	20000606
	US 2003004351	A1	20030102	US 2001-924431	20010808
	US 6541503	B2	20030401		
	US 2003069430	A1	20030410	US 2001-999331	20011130
PRAI	GB 1997-18913	A	19970905		
	WO 1998-EP5559	W	19980903		
	US 1999-262351	A3	19990304		
	US 2000-486960	A3	20000606		
OS	MARPAT 130:267341				
GI					



AB Title compds. [I; X = N, CH, CCF<sub>3</sub>, CA; A = aliphatyl; R<sub>1</sub> = H, SH, OH, HOA, heterocyclyl, AHN, A<sub>2</sub>N, A<sub>2</sub>NCO, halo, cyano, NO<sub>2</sub>, etc.; R<sub>2</sub> = H, A, HONA, alkoxy, HOA, heterocyclyl, A<sub>2</sub>NSO<sub>2</sub>, halo, NO<sub>2</sub>, OH, ASO<sub>2</sub>, etc.; R<sub>3</sub> = H, A, OH, HOA, A<sub>2</sub>N, aryl, aryloxy, hydroxyaryl, heterocyclyl, hydroxyheterocyclyl, etc.; R<sub>4</sub> = SO<sub>3</sub>H, SO<sub>2</sub>A, A<sub>2</sub>N, A<sub>2</sub>NCO, heterocycllamino, heterocyclsulfonyl, etc.; R<sub>5</sub> = H; R<sub>1</sub>R<sub>2</sub>, R<sub>4</sub>R<sub>5</sub> = fused ring], were prep'd. Thus, (Z)-N-(3-hydroxy-2,2-dimethylpropyl)-4-[(7-oxo-6,7-dihydro-1-thia-3,6-diaza-as-indacen-8-ylidene)methyl]amino]benzenesulfonamide [prep'd. from 8-ethoxymethylene-6,8-dihydro-1-thia-3,6-diaza-as-indacen-7-one and 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide] inhibited protein kinases CDK1, CDK2, and UL97 with IC<sub>50</sub> = 1-10 nM.

IT 222035-64-5P 222036-09-1P 222037-12-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prep'n. of oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors)

RN 222035-64-5 CAPLUS

CN Benzenemethanesulfonamide, 4-[(2Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)hydrazino]-N-methyl- (9CI) (CA INDEX NAME)


10080926

Double bond geometry as shown.




RN 222036-09-1 CAPLUS  
CN Benzenesulfonamide, 4-[(2Z)-(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)hydrazino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 222037-12-9 CAPLUS  
CN Benzenemethanesulfonamide, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)hydrazino]-N-methyl- (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:166598 CAPLUS  
DN 130:209599  
TI Preparation of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.  
IN McNutt, Robert Walton, Jr.; Jung, David Kendall; Harris, Philip Anthony; Hunter, Robert Neil, III; Veal, James Marvin; Dickerson, Scott; Lackey, Karen Elizabeth; Peel, Michael Robert  
PA Glaxo Group Limited, UK  
SO PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 9910325	A1	19990304	WO 1998-EP4844	19980804
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,				

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,  
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9891584 A1 19990316 AU 1998-91584 19980804  
 EP 1003721 A1 20000531 EP 1998-943832 19980804  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI  
 JP 2002514228 T2 20020514 JP 1999-513839 19980804  
 ZA 9807037 A 20000207 ZA 1998-7037 19980805  
 US 6268391 B1 20010731 US 2000-446586 20000407  
 PRAI GB 1997-16557 A 19970806  
 WO 1998-EP4844 W 19980804  
 OS MARPAT 130:209599  
 GI




AB Title compds. [I; R1 = H; R1R2 = fused 5-10 membered aryl, heteroaryl, heterocycl; R2, R3 = H, HET, aryl, aliphatyl, cyano, NO<sub>2</sub>, halo, R10, OR<sub>10</sub>, SR<sub>10</sub>, SOR<sub>10</sub>, SO<sub>2</sub>R<sub>10</sub>, NR<sub>10</sub>R<sub>11</sub>, etc.; R4 = H, halo, NO<sub>2</sub>, cyano; R5 = H, (substituted) aliphatyl; R6, R7 = halo, cyano, NO<sub>2</sub>, CONR<sub>10</sub>R<sub>11</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, NR<sub>10</sub>R<sub>11</sub>, OR<sub>11</sub>; R8 = OH, NH<sub>2</sub>O<sub>2</sub>R<sub>12</sub>, NHCOCF<sub>3</sub>; R10 = H, halo, (substituted) aliphatyl, aryl, HET; R11 = H, R10; R12 = H, (substituted) aliphatyl, HET; HET = benzofuryl, benzoazazolyl, dioxanyl, dithianyl, dithiazinyl, furyl, imidazolyl, indolyl, indazolyl, morpholinyl, tetrazolyl, pyrrolyl, quinolinyl, triazinyl, tetrahydrofuryl, etc.], were prepd. for treatment of tumor growth, preventing organ transplant rejection, healing chronic wounds, etc. (no data). Thus, 5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one hydrochloride (prepn. given) was stirred with 3,5-dibromo-4-hydroxybenzaldehyde in AcOH/aq. HCl to give 64% 3-(3,5-dibromo-4-hydroxybenzylidene)-5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one.

IT 220904-76-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.)

RN 220904-76-7 CAPLUS

CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10080926

AN 1998:682353 CAPLUS  
DN 129:302450  
TI Preparation of iodobenzamides as antineoplastic and antiviral agents  
IN Yatscoff, Randall W.; Foster, Robert T.; Naicker, Selvaraj  
PA Isotechnika, Inc., Can.  
SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845253	A1	19981015	WO 1998-IB768	19980410
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9870742	A1	19981030	AU 1998-70742	19980410
	EP 973727	A2	20000126	EP 1998-917555	19980410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001521510	T2	20011106	JP 1998-542547	19980410
	US 6225323	B1	20010501	US 1998-125173	19980811
	US 6306871	B1	20011023	US 2000-665654	20000919
PRAI	US 1997-43360P	P	19970410		
	US 1998-43360P	A	19980410		
	WO 1998-IB768	W	19980410		
	US 1998-125173	A1	19980811		
OS	MARPAT	129:302450			
GI					




AB Title compds. [I; R = CONY (sic) wherein Y is a chelatings groups selected from the group of aliph., arom., heterocyclic, carbohydrate groups, and where Y and N together form a heterocyclic ring (sic); R1 = NO<sub>2</sub> or NH<sub>2</sub>; R<sub>2</sub>,R<sub>3</sub> = H, NO<sub>2</sub>, NH<sub>2</sub>;when R<sub>2</sub> = NH<sub>2</sub> R<sub>1</sub> and R<sub>3</sub> = H] having a chelating group, a thiol trapping group, and an activating group. The presumptive mechanism of action in preventing cancer cell and virus replication is through inhibition of the binding of transcription factors to Zn finger binding domains. Thus, I (R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = NO<sub>2</sub>) (II; R = CO<sub>2</sub>H) was amidated by H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> to give II (R = CONHCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>). Data for biol. activity of I were given.

IT 214556-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of iodobenzamides as antineoplastic and antiviral agents)

RN 214556-50-0 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinolin-5-ol, 1-chloro-2,3-dihydro-3-(2-iodo-5-nitrobenzoyl)- (9CI) (CA INDEX NAME)




10080926

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS  
AN 1994:534101 CAPLUS  
DN 121:134101  
TI Preparation of quinoline derivative or salt thereof and remedy for cardiac diseases containing the same  
IN Kyotani, Yoshinori; Ogiya, Tadaaki; Toma, Tsutomu; Kurihara, Yuji; Kitamura, Takahiro; Yamaguchi, Takashi; Onogi, Kazuhiro; Sato, Seichi; Shigyo, Hiromichi; et al.  
PA Kowa Co., Ltd., Japan  
SO PCT Int. Appl., 265 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9322317	A1	19931111	WO 1993-JP566	19930428
	W: CA, JP, KR, US			RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	
	EP 638571	A1	19950215	EP 1993-911951	19930428
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 3406600	B2	20030512	JP 1993-519131	19930428
	US 5576324	A	19961119	US 1994-325270	19941027
PRAI	JP 1992-112862	A	19920501		
	WO 1993-JP566	W	19930428		
OS	MARPAT	121:134101			
GI	For diagram(s), see printed CA Issue.				
AB	Quinoline derivs. [I; ring A = a furan, dihydrofuran or dioxolane ring; R1 = OH, CO2H, alkoxy carbonyl, CONH2, alkenyl, CHO, cyano, (un)substituted alkyl, C(:NR10)R9; R9 = NH2, alkyl; R10 = H, OH; R2 = H, (un)substituted alkyl, alkenyl, acyl, OH; R3, R4 = H, halo, (un)substituted alkyl or NH2, alkoxy, alkylthio, CO2H, alkoxy carbonyl, acyl, CONH2, cyano, NO2; R5, R6, R7, R8 = H or alkyl; m = an integer 0-3; symbol.....means that there may be a double bond formed by R6 and R8] and medicinally acceptable salts are prep'd. The compds. I have a pos. inotropic effect on myocardia and an antiarrhythmic effect and can dilate blood vessels without extremely increasing the heart rate. Therefore, a remedy for cardiac diseases contg. I as the active ingredient is remarkably useful for treating cardiac insufficiency and arrhythmia and as vasodilators and cardiotonics. Thus, 5-hydroxy-6-allyl-8-methylcarbostyryl was stirred with m-chloroperbenzoic acid in CHCl3 at 50.degree. for 17 h to give a tetrahydrofuroquinolinone deriv. (II; X = OH, R9 = H) which was mesylated by MeSO2Cl in pyridine and underwent azidolysis with Na3 DMF at 100.degree. to give, after hydrogenation over 10% Pd-C, II (X = NH2, R11 = H). II.HCl (X = NH2, R11 = Me) at 100 mg/kg p.o. inhibited the CHCl3-induced arrhythmia in mice by 100%.				
IT	156934-75-7P	156934-76-8P	156934-77-9P		
	156934-78-0P	156934-79-1P	156935-57-8P		
	156935-58-9P	156935-59-0P			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as medicament for cardiac diseases)				
RN	156934-75-7	CAPLUS			
CN	Furo[3,2-f]quinolin-7(6H)-one, 1,2-dihydro-2-methyl-	(9CI)	(CA INDEX NAME)		




16~

RN 156934-76-8 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 1,2-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)


10080926




RN 156934-77-9 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 1,2-dihydro-2-[(methylsulfonyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 156934-78-0 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 2-(azidomethyl)-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 156934-79-1 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 2-(aminomethyl)-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 156935-57-8 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 2-(bromomethyl)-1,2-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 156935-58-9 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 2-(azidomethyl)-1,2-dihydro-5-methyl- (9CI) (CA INDEX NAME)

10080926



RN 156935-59-0 CAPLUS  
CN Furo[3,2-f]quinolin-7(6H)-one, 2-(aminomethyl)-1,2-dihydro-5-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d his

(FILE 'HOME' ENTERED AT 18:46:48 ON 03 JUN 2003)

FILE 'REGISTRY' ENTERED AT 18:46:57 ON 03 JUN 2003  
L1 STRUCTURE uploaded  
L2 4 S L1

FILE 'STNGUIDE' ENTERED AT 18:48:12 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:48:59 ON 03 JUN 2003  
L3 STRUCTURE uploaded  
L4 2 S L3

FILE 'STNGUIDE' ENTERED AT 18:50:17 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:52:33 ON 03 JUN 2003  
L5 STRUCTURE uploaded  
L6 9 S L5

FILE 'STNGUIDE' ENTERED AT 18:53:30 ON 03 JUN 2003

FILE 'STNGUIDE' ENTERED AT 18:57:42 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:57:50 ON 03 JUN 2003  
L7 STRUCTURE uploaded  
L8 8 S L7

FILE 'STNGUIDE' ENTERED AT 19:01:11 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 19:04:54 ON 03 JUN 2003  
L9 STRUCTURE uploaded  
L10 7 S L9  
L11 372 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:06:03 ON 03 JUN 2003  
L12 78 S L11  
L13 10 S L11/THU



=> s l12 not l13  
L14 68 L12 NOT L13

=> s l14 and patent/dt  
4107461 PATENT/DT  
L15 11 L14 AND PATENT/DT

=> d 1-11 bib abs hitstr

L15 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:676012 CAPLUS  
 DN 137:216935  
 TI Preparation of pyrroloindoles and pyrroloquinolines as prodrugs for tumor treatment  
 IN Searcey, Mark; Patterson, Laurence Hylton  
 PA School of Pharmacy, University of London, UK  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002068412	A1	20020906	WO 2002-GB796	20020222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI EP 2001-301636		A	20010222	
OS MARPAT		137:216935		
GI				



AB Title compds. I and II [wherein X = H; Y = leaving group; R1 = Ar, NH2, R8, or OR8; R2 and R4 = independently H, alkyl, OH, alkoxy, CN, Cl, Br, I, NO2, NH2, NHCOR9, CO2H, CONHR9, NHCO2R9, CO2R9, and COAr1; R3 = H, alkyl, OH, alkoxy, CN, Cl, Br, I, NO2, NH2, NHCOR9, CO2H, CONHR9, NHCO2R9, or CO2R9; R8 and R9 = independently alkyl or (un)substituted (hetero)aryl and ligands; Ar = (un)substituted specified (hetero)aryl, (hetero)cyclol, or phenylethenyl; Ar1 = Ar with provisos] were prep'd. as prodrug analogs of duocarmycin. For example, Et 5-nitroindole-2-carboxylate was protected with benzoyl chloride (87%) and the product hydrogenated with 10% Pd/C to give Et 5-amino-1-benzoylindole-2-carboxylate (40%). Iodation with N-iodosuccinimide (51%), BOC-protection (90%) of the amine, and addn. of 1,3-dichloropropene (94%) afforded the 5-[N-BOC-N-(3-chloro-2-propen-1-yl)amino]-4-iodoindole. Cyclization with Bu3SnH in the presence of AIBN in toluene (78%), followed by addn. of 5-methoxyindole-2-carboxylic acid (86%) produced III. The latter exhibited an activity factor, i.e. the ratio of IC50 cytotoxicity values obtained for pos. and neg. activation of CHO cells, of 71.7. Cytochrome P 450, which is expressed at high levels in tumors, is expected to hydroxylate I and II at the C atom to which X is joined. Thus, the prodrug is expected to be activated preferentially in

10080926

tumor cells, where it will act as a DNA alkylating agent preventing cell division.


IT 454691-89-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of pyrroloindoles and pyrroloquinolines as duocarmycin prodrugs for tumor treatment)

RN 454691-89-5 CAPLUS

CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 3-benzoyl-3,7-dihydro-, 6-(1,1-dimethylethyl) 2-ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2001:564157 CAPLUS

DN 135:159969

TI 1, 2-Dithiophene-yl-ethylene organic electroluminescent component  
IN Higuchi, Shoji; Sakaki, Yuichi; Yoshida, Tamotsu; Nagasaki, Yoshinori;  
Tanaka, Kazuhiko

PA Toppan Printing Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF

DT Patent


LA Japanese

FAN-CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001210472	A2	20010803	JP 2000-17332	20000126
PRAI	JP 2000-17332		20000126		
OS	MARPAT 135:159969				

GI

Not prior art



AB The invention refers to an org. electroluminescent component comprising 1,2 -dithiophene-yl-ethylene I [X, Y = C, or N; R, R1 = H, alkyl, alkoxy, tris-alkyl-siloxy or tris-alkyl-siloxy methyl].

IT 342807-14-1P 342807-16-3P


RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(1, 2-dithiophene-yl-ethylene org. electroluminescent component)

RN 342807-14-1 CAPLUS


CN Thieno[3,2-f]quinoline, 2,2'-(1E)-1,2-ethenediylbis- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10 ✓


10080926



RN 342807-16-3 CAPLUS

CN Thieno[3,2-f]quinoline, 2-[(1E)-2-[7-[(butyldimethylsilyl)oxy]methyl]benzo[1,2-b:4,3-b']dithien-2-yl]ethenyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 182631-27-2 190512-41-5, Thieno[3,2-f]quinoline-2-carboxaldehyde

RL: RCT (Reactant); RACT (Reactant or reagent)  
(1, 2-dithiophene-yl-ethylene org. electroluminescent component)

RN 182631-27-2 CAPLUS


CN Phosphonium, triphenyl(thieno[3,2-f]quinolin-2-ylmethyl)-, chloride (9CI) (CA INDEX NAME)



● Cl-

RN 190512-41-5 CAPLUS

CN Thieno[3,2-f]quinoline-2-carboxaldehyde (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2001:403451 CAPLUS

DN 135:19545

TI Preparation of 1,2-dithiophenylethylene as blue organic electroluminescent materials

IN Higuchi, Shoji; Tanaka, Kazuhiko; Sakaki, Yuichi; Yoshida, Tamotsu;  
Nagasaki, Yoshinori

PA Toppan Printing Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001151781	A2	20010605	JP 1999-335039	19991125
PRAI JP 1999-335039		19991125		

*not prior art*

10080926

OS MARPAT 135:19545  
GI




AB Title compds. I (X, Y = CH, N; R, R' = H, alkyl, alkoxy, trisalkylsiloxyethyl) are prep'd. 6-(Tert-butyldimethylsiloxy)naphtho[2,1-b]thiophene-2-carbaldehyde was reacted with 2-naphtho[2,1-b]thienylmethyltriphenylphosphonium chloride in the presence of tert-BuOK in MeOH at 0.degree. overnight to give 90% 2-[6'-(tert-butyldimethylsiloxy)naphtho[2,1-b]thienylmethyl]naphtho[2,1-b]thiophene showing strong blue fluorescence at peak wavelength 435 nm and 462 nm in PhMe.

IT 182631-27-2P 190512-41-5P, Thieno[3,2-f]quinoline-2-carboxaldehyde 342807-16-3P  
RL: PNU (Preparation, unclassified); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of dithiophenylethylene as blue org. electroluminescent materials)

RN 182631-27-2 CAPLUS


CN Phosphonium, triphenyl(thieno[3,2-f]quinolin-2-ylmethyl)-, chloride (9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

RN 190512-41-5 CAPLUS


CN Thieno[3,2-f]quinoline-2-carboxaldehyde (9CI) (CA INDEX NAME)



RN 342807-16-3 CAPLUS

CN Thieno[3,2-f]quinoline, 2-[(1E)-2-[7-[(butyldimethylsilyl)oxy]methyl]benzo[1,2-b:3-b']dithien-2-yl]ethenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10080926


IT 342807-14-1P

RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
(prepn. of dithiophenylethylene as blue org. electroluminescent materials)

RN 342807-14-1 CAPLUS

CN Thieno[3,2-f]quinoline, 2,2'-(1E)-1,2-ethenediylbis- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2001:73457 CAPLUS

DN 134:128209

TI Light-triggered indicators that memorize analyte concentrations

IN Tsien, Roger Y.; Adams, Stephen R.

PA The Regents of the University of California, USA

SO U.S., 18 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6180411	B1	20010130	US 1998-134668	19980730
PRAI	US 1997-54441P	P	19970801		
OS	MARPAT	134:128209			
GI					



I

AB A new class of optical indicators which are capable of memorizing and preserving the spatial localization of intracellular analytes in a time resolved manner is described. The compds. comprise a chromophore carrying a photolabile group capable of undergoing an irreversible and detectable chem. transformation upon irradn. by light. The chromophore is linked to a binding site capable of binding an analyte, wherein binding of the analyte to the binding site alters an optical property of the chromophore, thus altering the ability of the photolabile group to undergo the chem. transformation. Methods and kits for memorizing the spatial localization of the analytes are also described. A memory indicator for Ca2+, I, was prep'd. and tested.

IT 321939-03-1D, compds.


RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(as memory indicator for hydrogen ion; light-triggered indicators that memorize analyte concns.)

RN 321939-03-1 CAPLUS

CN Glycine, N-[2-[(1E)-2-[1-azido-2-benzoyl-5-[bis(carboxymethyl)amino]furo[3',2-f]quinolin-7-yl]ethenyl]phenyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10080926




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS  
AN 1997:754358 CAPLUS  
DN 128:61380  
TI Preparation of pyrroloquinolines as intermediates for duocarmycin SA  
IN Natsume, Mitsutaka; Muratake, Hideaki  
PA Shionogi and Co., Ltd., Japan; Otsu, Kenkyusho  
SO Jpn. Kokai Tokkyo Koho, 7 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09301975	A2	19971125	JP 1996-116052	19960510
PRAI JP 1996-116052		19960510		
OS CASREACT 128:61380; MARPAT 128:61380				

GI




AB Pyrroloquinolines I (R1 = H, lower alkyl; R2 = OH-protecting group; R3 = H, lower alkyl, amino-protecting group) are prepd. by intramol. cyclization of II (R1, R3 = same as above; R4 = halo, F3CSO3) using org. metal catalysts followed by protection of OH groups of I (R1, R3 = same as above; R2 = H). II (R1 = Me, R3 = H, R4 = F3CSO3) (prepn. given) was etherified with F3CSO3SiMe2Bu-t and Et3N in CH2Cl2 at 0.degree. for 1 h, cyclocondensed in the presence of Bu3SnF, (Ph3P)2PdCl2, and LiCl in xylene under reflux for 1 h, and protected with ClCO2H in pyridine at 20.degree. for 3 h to give 89% I (R1 = Me, R2 = MeOOC, R3 = H) (III). Me (7bR\*,8aS\*)-1,2,4,5,8,8a-hexahydro-4-oxocyclopropa[c]pyrrolo[3,2-e]indole-6-carboxylate (prepd. from III via several steps) was treated with 2-(imidazol-1-yl-carbonyl)-5,6,7-trimethoxyindole in the presence of NaH in THF/HCONMe2 at 0.degree. for 4 h to give 60% duocarmycin SA.

IT 182180-61-6P  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of pyrroloquinolines by intramol. cyclization of acetylpyridinylpyrrole using org metal catalysts)

RN 182180-61-6 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-[(methoxycarbonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

10080926



L15 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1990:35883 CAPLUS

DN 112:35883

TI Quinoline, quinazoline, and cinnoline fungicides and their preparation  
IN Arnold, Wendell Ray; Coghlan, Michael Joseph; Krumkalns, Eriks Victor;  
Jourdan, Glen Phil; Suhr, Robert George

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 60 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 326330	A2	19890802	EP 1989-300658	19890125
	EP 326330	A3	19900822		
	EP 326330	B1	20020724		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 89029	A1	19930131	IL 1989-89029	19890123
	AU 8928728	A1	19890803	AU 1989-28728	19890124
	AU 626279	B2	19920730		
	AT 221051	E	20020815	AT 1989-300658	19890125
	ES 2176173	T3	20021201	ES 1989-300658	19890125
	ZA 8900626	A	19891227	ZA 1989-626	19890126
	CA 1340470	A1	19990330	CA 1989-589263	19890126
	FI 8900423	A	19890730	FI 1989-423	19890127
	FI 94523	B	19950615		
	FI 94523	C	19950925		
	CN 1034925	A	19890823	CN 1989-100472	19890127
	CN 1031263	B	19960313		
	DK 8900365	A	19890915	DK 1989-365	19890127
	BR 8900356	A	19890919	BR 1989-356	19890127
	JP 01246263	A2	19891002	JP 1989-19400	19890127
	JP 2559485	B2	19961204		
	HU 49790	A2	19891128	HU 1989-426	19890127
	HU 208611	B	19931228		
	KR 9710174	B1	19970621	KR 1989-872	19890127
	US 5145843	A	19920908	US 1989-334422	19890407
	US 5240940	A	19930831	US 1992-881957	19920512
PRAI	US 1988-150266	A	19880129		
	US 1989-334422	A3	19890407		

GI



AB The title compds. [I; X = CR5, N; R5 = H, Cl, Me; Y = CR10 if X = N, Y = CR10 or N if X = CR5; R10 = H, Cl, Br; Z = O, S, SO, SO2, etc.; R1-R4 = H, OH, NO2, halo, C1-4 alkyl, etc.; R1R2 or R2R3 can form a carbocyclic ring; A = C1-18 (un)satd. (un)substituted hydrocarbon chain optionally including a heteroatom], C3-8 cycloalkyl, cycloalkenyl, etc. were prep'd. as agrochem. fungicides. A mixt. of 4,7-dichloroquinoline and 4-FC6H4OH in xylene was refluxed 17 h at 144.degree.. addnl. 4-FC6H4OH was added and

10080926


refluxing was continued to give 73.2% 7-chloro-4-(4-fluorophenoxy)quinoline (II). II at 100 ppm gave 90-100% control of Erysiphe graminis tritici.

IT 124496-59-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as agrochem. fungicide)

RN 124496-59-9 CAPLUS

CN 7H-Cyclopenta[f]quinoline, 1-(4-fluorophenoxy)-8,9-dihydro- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1977:405939 CAPLUS

DN 87:5939

TI Pyrroloquinoline derivatives

IN Kost, A. N.; Yudin, L. G.; Yamashkin, S. A.

PA Moscow State University, USSR

SO U.S.S.R.

From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1977, 54(8), 95.

CODEN: URXXAF


DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 548608	T	19770228	SU 1975-2157204	19750716
PRAI	SU 1975-2157204		19750716		

GI



AB Pyrrolo[4,5-f]quinolines I (R = Me, Ph; R1, R2 = H, Me), pyrrolo[5,4-f]quinolines II, pyrrolo[4,5-g]quinolines, and pyrrolo[5,4-g]quinolines were prep'd. by treatment of 5- or 6-aminoindoles III with .beta.-diketones (RCO)2CH2 and cyclization of the resulting anils in the presence of a strong acid (e.g., H2SO4, polyphosphoric acid, or F3CCCO2H) at 80-160.degree.C.


IT 232-85-9DP, derivs.

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 232-85-9 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)

10080926




L15 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS  
AN 1969:481325 CAPLUS  
DN 71:81325  
TI 2-Methyl-3-(.beta.-aminoethyl-1H-pyrrolo[2,3-b]quinoline or  
1-(.beta.-aminoethyl)-2-methyl-3H-pyrrolo(3,2-f)quinoline  
IN Grandberg, I. I.; Yaryshev, N. G.  
PA Timiryazev, K. A., Agricultural Academy  
SO U.S.S.R.  
From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1969, 46(14),  
23.  
CODEN: URXXAF  
DT Patent  
LA Russian  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 241441		19690418	SU	19671215

AB The title compd. is prep'd. by treating 2- or 8-hydrazinoquinoline with Me .gamma.-chloropropyl ketone at boiling in an alc. medium, with subsequent sepn. of the desired product.

IT 23758-94-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 23758-94-3 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline, 1-(2-aminoethyl)-2-methyl- (8CI) (CA INDEX NAME)



L15 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2003 ACS  
AN 1969:79169 CAPLUS  
DN 70:79169  
TI Polymethine dyes  
IN Zhiryakov, V. G.; Abramenko, P. I.; Sennikova, N. I.  
PA All-Union Scientific-Research Cinema-Photographic Institute  
SO U.S.S.R.  
From: Izobret., Prom. Obraztsy, Tovarnye Znaki 1967, 44(13), 176-7.  
CODEN: URXXAF  
DT Patent  
LA Russian  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 198130		19670609	SU	19660722

GI For diagram(s), see printed CA Issue.

AB Polymethine dyes of the cyanine and merocyanine series, useful as optical sensitizers for AgCl-contg. photographic emulsions in the 520-790 m.mu. wavelength range, are prep'd. Thus, a mixt. of 0.72 g. 9-methylthieno[3,2-f]quinoline ethiodide (I), 0.7 g. HC(OEt)<sub>3</sub>, and 3 ml. PhNO<sub>2</sub> was heated for 30 min. at 180.degree.. The product was pptd. with Et<sub>2</sub>O, redissolved in 3 ml. EtOH, treated with 3 ml. of 10% aq. KI soln., and cooled to give 0.26 g. II, m. 261-3.degree., .lambda.EtOHmax. 729 m.mu., sensitization range 720-90 m.mu. with a max. at 760 m.mu.. Similar treatment of the 7-Me analog (III) of I gave IV (R = Et, Z = thieno[3,2-f]quinolin-7-ylidene), m. >300.degree., .lambda.EtOHmax. 635 m.mu., sensitization range 560-720 m.mu. with a max. at 670 m.mu.. A mixt. of 0.36 g. I and 0.3 g. V in 5 ml. EtOH was heated for 30 min. with 0.1 g. Et<sub>3</sub>N to give 0.3 g. VI, m. 232-4.degree. (EtOH), .lambda.EtOHmax. 625 m.mu., sensitization range to 700 m.mu. with a max. at 660 m.mu..

10080926

Similarly III and V gave the analog of VI, m. 241-3.degree. (EtOH),  $\lambda_{\text{max}}$ . EtOHmax. 584 m.mu., sensitization range 530-690 m.mu. with a max. at 620 m.mu.. Treatment of 2-[2-(N-phenylacetamido)vinyl]benzothiazole or its O or Se analogs with 7-methylthieno[3,2-f]quinoline meth-iodide (VII) and Et<sub>3</sub>N in Ac<sub>2</sub>O gave the following IV (R = Me) [ZH2, m.p.,  $\lambda_{\text{max}}$ . EtOHmax. (m.mu.), sensitization range (m.mu.), and sensitization max. (m.mu.) given]: 3-ethylbenzothiazoline, 261-3.degree. (EtOH), 593, to 680, 625; 3-ethylbenzoxazoline, 254-6.degree. (EtOH), 559, to 680, 590. Heating 0.36 g. VII with 0.18 g. p-Me<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CHO in 2 ml. pyridine in the presence of 0.05 g. piperidine at 100.degree. for 1 hr. gave 0.28 g. 7-(p-dimethylamino-omega-styryl)thieno[3,2-f]quinoline methiodide, m. 277-9.degree. (EtOH),  $\lambda_{\text{max}}$ . EtOHmax. 528 m.mu., sensitizing range to 600 m.mu. with a max. at 580 m.mu..


IT 20048-75-3P 20048-76-4P 20048-79-7P

20048-80-0P 20048-81-1P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(prepn. of)


RN 20048-75-3 CAPLUS

CN Thieno[3,2-f]quinolinium, 6-ethyl-9-[3-(6-ethylthieno[3,2-f]quinolin-9(6H)-ylidene)propenyl]-, iodide (8CI) (CA INDEX NAME)



RN 20048-76-4 CAPLUS


CN Thieno[3,2-f]quinolinium, 6-ethyl-7-[3-(6-ethylthieno[3,2-f]quinolin-7(6H)-ylidene)propenyl]-, iodide (8CI) (CA INDEX NAME)



RN 20048-79-7 CAPLUS


CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-6-methyl-, iodide (8CI) (CA INDEX NAME)

10080926




● I -

RN 20048-80-0 CAPLUS  
CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzoselenazolinylidene)propenyl]-6-methyl-, iodide (8CI) (CA INDEX NAME)



● I -

RN 20048-81-1 CAPLUS  
CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzoxazolinylidene)propenyl]-6-methyl-, iodide (8CI) (CA INDEX NAME)



● I -

L15 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1968:468262 CAPLUS

DN 69:68262

TI Polymethine dyes

IN Zharyakov, V. G.; Abramenko, P. I.; Sennikova, N. I.

PA All-Union Scientific-Research Cinema-Photographic Institute

SO U.S.S.R.

From: Izobret., Prom. Obraztsy, Tovarnye Znaki 1967, 44(13), 176-7.

CODEN: URXXAF

DT Patent

LA Russian

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI SU 198130	19670609	SU	19660722	
--------------	----------	----	----------	--

GI For diagram(s), see printed CA Issue.

AB Polymethine dyes suitable for the optical sensitization of Ag halide photographic emulsions have the general formulas I-III, where R is alkyl; Z is a 7- or 9-thieno[3,2-f]quinoline residue; Z' is a benzothiazole, benzoxazole, benzoselenazole, 7- or 9-thieno [3,2-f] quinoline residue; and X is an acid residue. These dyes are prep'd. by condensing quaternary salts of 7- or 9-methylthieno [3,2-f] quinoline with intermediates such as HC(OEt)3, 3-ethyl-5-(.alpha.acetylaminomethylene)thiazolidine-2-thion-4-one, 2-(.beta.-acetanilinovinyl)benzothiazole, or 4-Me2NC6H4CHO.

IT 20048-75-3P 20048-76-4P 20048-78-6P

10080926


20048-79-7P 20048-80-0P 20048-81-1P

20048-82-2P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(prepn. of)

RN 20048-75-3 CAPLUS


CN Thieno[3,2-f]quinolinium, 6-ethyl-9-[3-(6-ethylthieno[3,2-f]quinolin-9(6H)-  
ylidene)propenyl]-, iodide (8CI) (CA INDEX NAME)



● I-

RN 20048-76-4 CAPLUS


CN Thieno[3,2-f]quinolinium, 6-ethyl-7-[3-(6-ethylthieno[3,2-f]quinolin-7(6H)-  
ylidene)propenyl]-, iodide (8CI) (CA INDEX NAME)



● II-

RN 20048-78-6 CAPLUS


CN Rhodanine, 3-ethyl-5-[2-(6-ethylthieno[3,2-f]quinolin-7(6H)-  
ylidene)ethyldiene]- (8CI) (CA INDEX NAME)



RN 20048-79-7 CAPLUS

CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-  
6-methyl-, iodide (8CI) (CA INDEX NAME)


10080926



● I -

RN 20048-80-0 CAPLUS


CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzoselenazolinylidene)propenyl]-6-methyl-, iodide (8CI) (CA INDEX NAME)



● I -

RN 20048-81-1 CAPLUS


CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzoxazolinylidene)propenyl]-6-methyl-, iodide (8CI) (CA INDEX NAME)



● I -

RN 20048-82-2 CAPLUS

CN Thieno[3,2-f]quinolinium, 7-[p-(dimethylamino)styryl]-6-methyl-, iodide (8CI) (CA INDEX NAME)



● I -

L15 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 1968:88212 CAPLUS

DN 68:88212

TI Polymethine dyes of the cyanine and merocyanine blue-type

IN Abramenko, P. I.; Sennikova, N. I.

PA All-Union Scientific-Research Institute of Chemical-Photographic Industry

10080926

SO U.S.S.R.

From: Izobret., Prom. Obraztsy, Tovarnye Znaki 1967, 44(16), 183.

CODEN: URXXAF

DT Patent

LA Russian

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI SU 200426 19670713 SU 19661110

GI For diagram(s), see printed CA Issue.


AB The title compds. of the general formulas I and II, where R is alkyl, Z is a 1-methylthionaphtheno[3,2-b]-3-pyridine residue, or a 9-methylthieno[3,2-f]-7-quinoline residue, Z1 is a benzothiazole residue or a 9-methylthieno[3,2-f]-7-quinoline residue, and X- is an anion, are useful for optical sensitization of silver halide photographic emulsions. They are prep'd. from quaternary salts of 1,3-dimethylthionaphtheno[3,2-b]pyridine (III) or 7,9-dimethylthieno[3,2-f]quinoline (IV) by condensation with intermediates usually used in the synthesis of polymethine dyes, e.g. HC(OEt)3, 3-ethyl-5-(acetanilidomethylene)thiazolidine-2-thion-4-one, and 2-(.beta.-acetanilidovinyl)benzothiazole.

IT 19132-41-3P 19132-42-4P 20324-86-1P

RL: IMF (Industrial manufature); PREP (Preparation)  
(prepn. of)


RN 19132-41-3 CAPLUS

CN Rhodanine, 5-[2-(6,9-dimethylthieno[3,2-f]quinolin-7(6H)-ylidene)ethylidene]-3-ethyl- (8CI) (CA INDEX NAME)



RN 19132-42-4 CAPLUS


CN Thieno[3,2-f]quinolinium, 7-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-6,9-dimethyl-, iodide (8CI) (CA INDEX NAME)



● I-

RN 20324-86-1 CAPLUS

CN Thieno[3,2-f]quinolinium, 6-[3-(6,9-dimethylthieno[3,2-f]quinolin-7(6H)-ylidene)propenyl]-6,9-dimethyl-, iodide (8CI) (CA INDEX NAME)



I-

10080926

=> d his

(FILE 'HOME' ENTERED AT 18:46:48 ON 03 JUN 2003)

FILE 'REGISTRY' ENTERED AT 18:46:57 ON 03 JUN 2003

L1           STRUCTURE UPLOADED

L2           4 S L1

FILE 'STNGUIDE' ENTERED AT 18:48:12 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:48:59 ON 03 JUN 2003

L3           STRUCTURE UPLOADED

L4           2 S L3

FILE 'STNGUIDE' ENTERED AT 18:50:17 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:52:33 ON 03 JUN 2003

L5           STRUCTURE UPLOADED

L6           9 S L5

FILE 'STNGUIDE' ENTERED AT 18:53:30 ON 03 JUN 2003

FILE 'STNGUIDE' ENTERED AT 18:57:42 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 18:57:50 ON 03 JUN 2003

L7           STRUCTURE UPLOADED

L8           8 S L7

FILE 'STNGUIDE' ENTERED AT 19:01:11 ON 03 JUN 2003

FILE 'REGISTRY' ENTERED AT 19:04:54 ON 03 JUN 2003

L9           STRUCTURE UPLOADED

L10          7 S L9

L11          372 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:06:03 ON 03 JUN 2003

L12          78 S L11

L13          10 S L11/THU

L14          68 S L12 NOT L13

L15          11 S L14 AND PATENT/DT

=> d l14 not l15

L15 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l14 not l15

L16          57 L14 NOT L15

=> d 1,5,10,15,20,25,30,35,40,45,50,55,57 bib abs hitstr

L16 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2003 ACS

AN 2002:338062 CAPLUS

DN 137:232531

TI Novel facile synthesis of 2,2,4-substituted-1,2-dihydroquinolines via a modified Skraup reaction

AU Theoclitou, Maria-Elena; Robinson, Leslie A.

CS Pharma Research Laboratories, Bristol-Myers Squibb, San Diego, CA, 92121, USA

SO Tetrahedron Letters (2002), 43(21), 3907-3910

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 137:232531


AB A variety of 2,2,4-substituted-1,2-dihydroquinolines were synthesized from substituted anilines or amino heterocycles and the corresponding ketones in good yield via the use of lanthanide catalysts and microwave technol. This method can be readily applied to the general synthesis of combinatorial libraries of dihydroquinolines.

IT 459169-97-2P 459170-00-4P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(microwave Skraup prepn. of dihydroquinolines)

RN 459169-97-2 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline, 6,7-dihydro-7,7,9-trimethyl- (9CI) (CA INDEX NAME)




RN 459170-00-4 CAPLUS  
 CN 3H-Pyrrolo[3,2-f]quinoline, 7,9-diethyl-6,7-dihydro-7-methyl- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


- L16 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001:795458 CAPLUS  
 DN 136:102256  
 TI Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis  
 AU Bramson, H. Neal; Corona, John; Davis, Stephen T.; Dickerson, Scott H.; Edelstein, Mark; Frye, Stephen V.; Gampe, Robert T., Jr.; Harris, Phil A.; Hassell, Anne; Holmes, William D.; Hunter, Robert N.; Lackey, Karen E.; Lovejoy, Brett; Luzzio, Michael J.; Montana, Val; Rocque, Warren J.; Rusnak, David; Shewchuk, Lisa; Veal, James M.; Walker, Duncan H.; Kuyper, Lee F.  
 CS GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA  
 SO Journal of Medicinal Chemistry (2001), 44(25), 4339-4358  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Two closely related classes of oxindole-based compds., 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compd. was prep'd. as a homolog of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor. Crystallog. anal. of the lead compd. bound to CDK2 provided the basis for analog design. A semiautomated method of ligand docking was used to select compds. for synthesis, and a no. of compds. with low nanomolar inhibitory activity vs. CDK2 were identified. Enzyme binding determinants for several analogs were evaluated by X-ray crystallog. Compds. in this series inhibited CDK2 with a potency .apprx.10-fold greater than that for CDK1. Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.  
 IT 388627-23-4P 388627-25-6P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones as inhibitors of cyclin-dependent kinase 2)  
 RN 388627-23-4 CAPLUS  
 CN Benzenesulfonamide, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)hydrazinol-, hydrochloride (4:3) (9CI) (CA INDEX NAME)

10080926




3/4 HCl


RN 388627-25-6 CAPLUS  
CN Benzenesulfonamide, 4-[(2,3-dihydro-2-oxo-1H-pyrrolo[3,2-f]quinolin-1-ylidene)amino]- (9CI) (CA INDEX NAME)



IT 220904-94-9, 1H-Pyrrolo[3,2-f]quinoline-1,2(3H)-dione  
388628-24-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of 1H-indole-2,3-dione 3-phenylhydrazones and  
3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones as inhibitors of  
cyclin-dependent kinase 2)  
RN 220904-94-9 CAPLUS  
CN 1H-Pyrrolo[3,2-f]quinoline-1,2(3H)-dione (9CI) (CA INDEX NAME)



RN 388628-24-8 CAPLUS  
CN 2H-Pyrrolo[3,2-f]quinolin-2-one, 1-[(dimethylamino)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD

10080926

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 57 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:716681 CAPLUS  
DN 132:49819  
TI Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs  
AU Asai, Akira; Nagamura, Satoru; Kobayashi, Eiji; Gomi, Katsuhige; Saito, Hiromitsu  
CS Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd, Machida, 194-8533, Japan  
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(20), 2995-2998  
CODEN: BMCL8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
GI



AB The water-sol. duocarmycin B1 prodrugs such as I (R = .beta.-D-glucopyranosyl; (OH)2OP; N-methylpiperazinylcarbonyl) were synthesized for improving biol. and pharmaceutical profiles of duocarmycin. Among these prodrugs, I (R = N-methylpiperazinylcarbonyl) exhibited potent antitumor activity against several human tumors in vivo.


IT 252959-11-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and antitumor activity of water-sol. duocarmycin B1 prodrugs)

RN 252959-11-8 CAPLUS

CN 1H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 2,3,6,7-tetrahydro-2-methyl-4-[(4-methyl-1-piperazinyl)carbonyl]oxy]-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 57 CAPLUS COPYRIGHT 2003 ACS

10080926

AN 1998:226505 CAPLUS

DN 128:294622

TI Synthesis of duocarmycin SA by way of methyl 4-(methoxycarbonyl)oxy-3H-pyrrolo[3,2-f]quinoline-2-carboxylate as a tricyclic heteroaromatic intermediate

AU Muratake, Hideaki; Tonegawa, Miyuki; Natsume, Mitsutaka

CS Research Foundation Itsuu Laboratory, Tokyo, 158, Japan

SO Chemical & Pharmaceutical Bulletin (1998), 46(3), 400-412

CODEN: CPBTAL; ISSN: 0009-2363



PB Pharmaceutical Society of Japan

DT Journal


LA English

OS CASREACT 128:294622

GI



II



III

AB The new synthetic path proposed that a fully arom. I would afford the dihydropyridine deriv. II ( $X=Y=CH=CH$ ,  $Z=CH_2$ ;  $X=CH_2$ ,  $Y=Z=CH=CH$ ) on partial redn. and by making use of the double bonds formed, a hydroxyl group could be introduced at the required position either in a racemic or in an asym. way to yield III. The Stille coupling product obtained from the bromopyrrole with the stannylpyridine represented a potential precursor. Both Sharpless asym. dihydroxylation (AD) and Jacobsen's asym. epoxidn. were applied to II ( $X=Y=CH=CH$ ,  $Z=CH_2$ ;  $X=CH_2$ ,  $Y=Z=CH=CH$ ). At the best, 81% ee was obsd. in the AD reaction of II ( $X=Y=CH=CH$ ,  $Z=CH_2$ ) using 2,5-diphenyl-4,6-bis(9-O-dihydroquinalyl)pyrimidine [(DHQ)<sub>2</sub>PYR], but the product possessed an unnatural abs. configuration. Formal syntheses of (+--)-duocarmycin SA, natural (+)-duocarmycin SA and unnatural (-)-duocarmycin SA were accomplished via a tricyclic heteroarom. compd. I.

IT 182180-07-0P 182180-11-6P 182180-61-6P  
206115-48-2P 206115-49-3P 206115-55-1P

206115-56-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of duocarmycin SA via the tricyclic heteroarom. intermediate Me 4-(methoxycarbonyl)oxy-3H-pyrrolo[3,2-f]quinoline-2-carboxylate)


RN 182180-07-0 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-(2,2-dimethyl-1-oxopropoxy)-, methyl ester (9CI) (CA INDEX NAME)


10080926




RN 182180-11-6 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 3,7-dihydro-4-[(methoxycarbonyl)oxy]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 182180-61-6 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-[(methoxycarbonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 206115-48-2 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 206115-49-3 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-(phenylmethoxy)-3-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



10080926


RN 206115-55-1 CAPLUS

CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 3,7-dihydro-4-(phenylmethoxy)-3-(phenylmethyl)-, 2-methyl 6-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 206115-56-2 CAPLUS

CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 7-cyano-4-(2,2-dimethyl-1-oxopropoxy)-3,7-dihydro-, dimethyl ester (9CI) (CA INDEX NAME)




IT 206115-47-1P 206115-50-6P 206115-52-8P  
206115-57-3P 206115-62-0P 206115-64-2P

206115-76-6P 206115-77-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of duocarmycin SA via the tricyclic heteroarom. intermediate Me 4-(methoxycarbonyl)oxy-3H-pyrrolo[3,2-f]quinoline-2-carboxylate)


RN 206115-47-1 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-[[tris(1-methylethyl)silyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 206115-50-6 CAPLUS


CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-(phenylmethoxy)-3,5-bis(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 206115-52-8 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-[(phenylmethoxy)methoxy]-3-[(phenylmethoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)


10080926




RN 206115-57-3 CAPLUS  
CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 9-cyano-4-(2,2-dimethyl-1-oxopropoxy)-3,7-dihydro-, dimethyl ester (9CI) (CA INDEX NAME)




RN 206115-62-0 CAPLUS  
CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 3,7-dihydro-4-(phenylmethoxy)-3-(phenylmethyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 206115-64-2 CAPLUS  
CN Boron, trihydro[methyl 4-(phenylmethoxy)-3-(phenylmethyl)-3H-pyrrolo[3,2-f]quinoline-2-carboxylate-.kappa.N6]-, (T-4)- (9CI) (CA INDEX NAME)




RN 206115-76-6 CAPLUS  
CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 7-cyano-4-(2,2-dimethyl-1-oxopropoxy)-3,7-dihydro-, 2-methyl 6-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 206115-77-7 CAPLUS  
CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 9-cyano-4-(2,2-dimethyl-1-oxopropoxy)-3,7-dihydro-, 2-methyl 6-(phenylmethyl) ester (9CI) (CA INDEX NAME)


10080926

INDEX NAME)




RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 57 CAPLUS COPYRIGHT 2003 ACS  
AN 1996:542111 CAPLUS  
DN 125:275476  
TI Alternative synthesis of duocarmycin SA using a tricyclic heteroaromatic intermediate prepared by palladium-catalyzed coupling reactions  
AU Muratake, Hideaki; Tonegawa, Miyuki; Natsume, Mitsutaka  
CS Research Foundation Itsuu Lab., Tamagawa, 158, Japan  
SO Chemical & Pharmaceutical Bulletin (1996), 44(8), 1631-1633  
CODEN: CPBTAL; ISSN: 0009-2363  
PB Pharmaceutical Society of Japan  
DT Journal  
LA English  
OS CASREACT 125:275476  
GI




I




II

AB Alternative synthesis of duocarmycin SA I was achieved by developing a novel prepn. method using palladium catalysts for a tricyclic heteroarom. compd. II ( $XX_1 = CH:CHCH:N$ ), followed by transformation into the previously reported intermediates via the alc. II [ $XX_1 = CH_2CH(OH)CH_2N(CO_2Me)$ ].  
IT 182180-07-0P 182180-11-6P 182180-61-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(novel prepn. of duocarmycin SA via the key tricyclic heteroarom. intermediate prepd. by palladium-catalyzed coupling reactions)  
RN 182180-07-0 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-(2,2-dimethyl-1-oxopropoxy)-, methyl ester (9CI) (CA INDEX NAME)


10080926




RN 182180-11-6 CAPLUS  
CN 6H-Pyrrolo[3,2-f]quinoline-2,6-dicarboxylic acid, 3,7-dihydro-4-[(methoxycarbonyl)oxy]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 182180-61-6 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid, 4-[(methoxycarbonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




L16 ANSWER 25 OF 57 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:628107 CAPLUS  
DN 123:82711  
TI Structural chemistry of polycyclic heteroaromatic compounds. Part 6. Photoelectron spectra and electronic structures of polycyclic heptarenes: thienoquinolines and thienoisouquinolines  
AU Marzinzik, A. L.; Rademacher, P.  
CS Institute of Organic Chemistry, University of Essen, Essen, D-45117, Germany  
SO Journal of Molecular Structure (1995), 351, 107-17  
CODEN: JMOSE4; ISSN: 0022-2860  
PB Elsevier  
DT Journal  
LA English  
AB The He(1) photoelectron spectra of 13 isomeric thienoquinolines and thienoisouquinolines and the  $\pi$ -isoelectronic naphthothiophenes are reported and discussed. The assignments for the latter compds. are made by using the sulfur double-bond model taking phenanthrene (I) as the ref. mol. The shape and the energies of the  $\pi$ . MOs of thienoquinolines and thienoisouquinolines can be estd. from those of I by first-order perturbation theory. This concept is very useful for distinguishing isomeric thienoquinolines and thienoisouquinolines.  
IT 233-03-4, Thieno[3,2-f]quinoline  
RL: PRP (Properties)  
(photoelectron spectra and electronic structures of thienoquinolines, thienoisouquinolines, and naphthothiophenes)  
RN 233-03-4 CAPLUS  
CN Thieno[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)




L16 ANSWER 30 OF 57 CAPLUS COPYRIGHT 2003 ACS  
 AN 1989:75273 CAPLUS  
 DN 110:75273  
 TI Reactivity of 1H-pyrrolo[2.3-f]-3H-pyrrolo[3.2-f]quinolines and their derivatives  
 AU Gryaznov, A. P.  
 CS Mosk. S-Kh. Akad., Moscow, USSR  
 SO Izvestiya Timiryazevskoi Sel'skokhozyaistvennoi Akademii (1988), (3), 185-90  
 CODEN: ITSAA7; ISSN: 0021-342X  
 DT Journal  
 LA Russian  
 OS CASREACT 110:75273  
 GI



AB The reactivity of isomeric pyrroloquinolines I ( $R = H$ ) and II ( $R = H$ ) and their derivs. I ( $R = CHO$ ) and II ( $R = CHO$ ) were investigated. Thus, I ( $R = H$ ) or II ( $R = H$ ) reacted with HCHO and Me<sub>2</sub>NH to give I ( $R = CH_2NMe_2$ ) and II ( $R = CH_2NMe_2$ )<sub>2</sub>, resp. Also, I ( $R = CHO$ ) and II ( $R = CHO$ ) reacted with CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub>, NH<sub>2</sub>NHC(:S)NH<sub>2</sub>, and NH<sub>2</sub>OH.HCl to give I [ $R = CHZ$ , Z = CH(CO<sub>2</sub>H), NNHC(:S)NH<sub>2</sub>, NOH] and II ( $R = CHZ$ ), resp.  
 IT 232-85-9, 3H-Pyrrolo[3,2-f]quinoline  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (formylation or aminomethylation of, reactivity in relation to)  
 RN 232-85-9 CAPLUS  
 CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)



IT 118644-73-8P, 1-Formyl-3H-pyrrolo[3,2-f]quinoline  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and condensation reactions of, reactivity in relation to)  
 RN 118644-73-8 CAPLUS  
 CN 3H-Pyrrolo[3,2-f]quinoline-1-carboxaldehyde (9CI) (CA INDEX NAME)



IT 118644-71-6P 118644-75-0P 118644-77-2P


10080926

118644-80-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 118644-71-6 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-1-methanamine, N,N-dimethyl- (9CI) (CA INDEX  
NAME)




RN 118644-75-0 CAPLUS

CN 2-Propenoic acid, 3-(3H-pyrrolo[3,2-f]quinolin-1-yl)- (9CI) (CA INDEX  
NAME)



RN 118644-77-2 CAPLUS


CN Hydrazinecarbothioamide, 2-(3H-pyrrolo[3,2-f]quinolin-1-ylmethylene)-  
(9CI) (CA INDEX NAME)



RN 118644-80-7 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-1-carboxaldehyde, oxime, (E)- (9CI) (CA INDEX  
NAME)

Double bond geometry as shown.



L16 ANSWER 35 OF 57 CAPLUS COPYRIGHT 2003 ACS

AN 1982:64053 CAPLUS

DN 96:64053

TI Isolation and identification of aza-arenes of tobacco smoke

AU Snook, M. E.; Fortson, P. J.; Chortyk, O. T.

CS Educ. Adm., USDA, Athens, GA, 30613, USA

SO Beitraege zur Tabakforschung International (1981), 11(2), 67-78  
CODEN: BTAID3; ISSN: 0173-783X

DT Journal

LA English

AB The N analogs of polynuclear arom. hydrocarbons (aza-arenes) were isolated and identified in a basic fraction of cigaret smoke condensate. Silicic acid chromatog. removed the predominant nicotine alkaloids, while gel chromatog. on Bio-Beads S-X12 in benzene effectively sepd. the aza-arenes

10080926


from interfering aliph. compds. In addn., the gel columns sepd. the aza-arenes by ring no. and degree of alkylation on the basis of an adsorption-type mechanism. These gel characteristics facilitated the identifications of a large no. of isomeric aza-arenes. Compds. identified included 2-vinylpyridine [100-69-6], 3-vinylpyridine [1121-55-7], and 2-phenylpyridine [1008-89-5] as well as quinoline [91-22-5], isoquinoline [119-65-3], 4-azafluorene [244-99-5], benzoquinolines, benzoisoquinolines, 1-azafluoranthene [206-56-4], 7-azafluoranthene [206-49-5], 4-azapyrene [194-03-6], 7-azaindole [271-63-6], pyrroloquinoline, and their mono-, di-, and tri-Me derivs. All 8 possible isomers of benzoquinoline and benzoisoquinoline were found, 4 of which are being reported for the 1st time. Evidence was also found for the probable presence of 5,6-benzo-7-azaindole [110-86-1].

IT 232-85-9

RL: ANST (Analytical study)  
(of tobacco smoke, isolation and identification of)

RN 232-85-9 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)



L16 ANSWER 40 OF 57 CAPLUS COPYRIGHT 2003 ACS

AN 1980:146650 CAPLUS

DN 92:146650

TI Nitropyrroloquinolines

AU Yudin, L. G.; Yamashkin, S. A.; Terent'ev, P. B.; Solov'ev, O. A.

CS Mosk. Gos. Univ., Moscow, 117234, USSR




SO Khimiya Geterotsiklicheskikh Soedinenii (1979), (10), 1381-5

CODEN: KGSSAQ; ISSN: 0453-8234

DT Journal

LA Russian

GI



AB Treatment of aminoindoles I (R = H, Me; R<sup>1</sup> = 5-H<sub>2</sub>N, 6-NH<sub>2</sub>) with O<sub>2</sub>NCH(CHO)<sub>2</sub> gave 79-86% I [R = H, Me; R<sup>1</sup> = 5-, 6-OCHC(NO<sub>2</sub>):CHNH] (II). Cyclocondensation of C-5 substituted II gave a mixt. of pyrroloquinolines III and IV in a 4:1 molar ratio. Similarly, C-6 substituted II (R = Me) gave a mixt. of V and VI in a 3:1 molar ratio. Mass spectra of III -VI were given.


10080926

IT 72793-29-4P 72793-30-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 72793-29-4 CAPLUS


CN 3H-Pyrrolo[3,2-f]quinoline, 1,2-dimethyl-8-nitro- (9CI) (CA INDEX NAME)



102

RN 72793-30-7 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline, 2-methyl-8-nitro- (9CI) (CA INDEX NAME)



102

L16 ANSWER 45 OF 57 CAPLUS COPYRIGHT 2003 ACS

AN 1977:468196 CAPLUS

DN 87:68196

TI Pyrroloquinolines. II. Synthesis of 1H-pyrrolo[2,3-f]- and  
3H-pyrrolo[3,2-f]quinolines

AU Gryaznov, A. P.; Akhvediani, R. N.; Volodina, T. A.; Vasil'ev, A. M.;  
Babushkina, T. A.; Suvorov, N. N.

CS Mosk. Khim.-Tekhnol. Inst. im. Mendeleva, Moscow, USSR


SO Khimiya Geterotsiklicheskikh Soedinenii (1977), (3), 369-76

CODEN: KGSSAQ; ISSN: 0132-6244

DT Journal

LA Russian

GI




AB Hydrazinoquinoline I (X = H<sub>2</sub>), prep'd. in 78% yield from the nitro deriv., was condensed with MeCOCO<sub>2</sub>Me to give 94% I (X = CMeCO<sub>2</sub>Et) as a mixt. of stereoisomers. Subsequent cyclization and sapon. gave 57% II (R = CO<sub>2</sub>H) which was decarboxylated to give 95% II (R = H). Analogously obtained was 95% III.

IT 63385-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and decarboxylation of)


RN 63385-16-0 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline-2-carboxylic acid (9CI) (CA INDEX NAME)




10080926

IT 232-85-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 232-85-9 CAPLUS  
CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)



Cause [initials]

L16 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2003 ACS  
AN 1971:3531 CAPLUS  
DN 74:3531  
TI Substitution reactions of thieno[3,2-f]quinoline  
AU Chapman, Norman Bellamy; Clarke, Kenneth; Sharma, K. S.  
CS Dep. Chem., Univ. Hull, Hull, UK  
SO Journal of the Chemical Society [Section] C: Organic (1970), (17), 2334-9  
CODEN: JSOOAX; ISSN: 0022-4952  
DT Journal  
LA English  
AB Mononitration, monobromination, and Friedel-Crafts acylation of thieno[3,2-f]quinoline occurred in the 2-position; dibromination in H<sub>2</sub>SO<sub>4</sub> gave the 1,2-dibromo deriv. The Hunsdiecker reaction of thieno[3,2-f]quinoline-2-carboxylic acid gave a mixt. of 1,2,5-tribromothieno[3,2-f]quinoline and 5-bromothieno[3,2-f]quinoline-2-carboxylic acid in addn. to unchanged starting material. Bromination of Na thieno[3,2-f]-quinoline-2-carboxylate gave the 5-bromo acid. N-Methylthieno[3,2-f]quinolinium hydrogen sulfate was oxidized to N-methylthieno[3,2-f]quinolin-7-one, which, on treatment with PCl<sub>5</sub>, gave 7-chlorothieno[3,2-f]quinoline. However, the methosulfate reacted with aq. KCN to give 6,9-dihydro-N-methylthieno[3,2-f]quinoline-9-carbonitrile which, when oxidized with iodine in pyridine yielded 9-cyano-N-methylthieno[3,2-f]quinoline iodide. Demethylation gave thieno[3,2-f]quinoline-9-carbonitrile. The Reissert compd. derived from thieno[3,2-f]-quinoline reacted with PCl<sub>5</sub> to yield thieno[3,2-f]quinoline-7-carbonitrile, which on hydrolysis with HCl yielded the 7-carboxylic acid.  
IT 29948-24-1P 29948-25-2P 29948-26-3P  
29948-27-4P 29970-37-4P 29970-38-5P  
29970-39-6P 29970-40-9P 29970-43-2P  
29970-44-3P 29970-45-4P 29970-46-5P  
29970-47-6P 29970-48-7P 29970-50-1P  
29970-51-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 29948-24-1 CAPLUS  
CN Thieno[3,2-f]quinoline, 1-methyl- (8CI) (CA INDEX NAME)




✓

RN 29948-25-2 CAPLUS  
CN Thieno[3,2-f]quinoline, 1-methyl-, monopicrate (8CI) (CA INDEX NAME)

CM 1


CRN 29948-24-1  
CMF C12 H9 N S

10080926




CM 2


CRN 88-89-1  
CMF C6 H3 N3 O7




RN 29948-26-3 CAPLUS  
CN Thieno[3,2-f]quinoline-2-carboxylic acid, ethyl ester (8CI, 9CI) (CA INDEX NAME)




RN 29948-27-4 CAPLUS  
CN Thieno[3,2-f]quinoline-2-carbonitrile (8CI) (CA INDEX NAME)



RN 29970-37-4 CAPLUS  
CN Thieno[3,2-f]quinoline, 2-bromo- (8CI) (CA INDEX NAME)




RN 29970-38-5 CAPLUS  
CN Thieno[3,2-f]quinoline, 2-nitro- (8CI) (CA INDEX NAME)




10080926

RN 29970-39-6 CAPLUS  
CN Ketone, methyl thieno[3,2-f]quinolin-2-yl (8CI) (CA INDEX NAME)




RN 29970-40-9 CAPLUS  
CN Ketone, methyl thieno[3,2-f]quinolin-2-yl, (2,4-dinitrophenyl)hydrazone (8CI) (CA INDEX NAME)



RN 29970-43-2 CAPLUS  
CN Thieno[3,2-f]quinolinium, 6-methyl-, methyl sulfate (8CI) (CA INDEX NAME)

CM 1

CRN 46255-83-8  
CMF C12 H10 N S




CM 2

CRN 21228-90-0  
CMF C H3 O4 S


Me-O-SO<sub>3</sub><sup>-</sup>

RN 29970-44-3 CAPLUS  
CN Thieno[3,2-f]quinolin-7(6H)-one, 6-methyl- (8CI) (CA INDEX NAME)




RN 29970-45-4 CAPLUS  
CN Thieno[3,2-f]quinoline, 7-chloro- (8CI) (CA INDEX NAME)


10080926




RN 29970-46-5 CAPLUS  
CN Thieno[3,2-f]quinoline-7-carbonitrile, 6-benzoyl-6,7-dihydro- (8CI) (CA INDEX NAME)




RN 29970-47-6 CAPLUS  
CN Thieno[3,2-f]quinoline-7-carbonitrile (8CI, 9CI) (CA INDEX NAME)




RN 29970-48-7 CAPLUS  
CN Thieno[3,2-f]quinoline-7-carboxylic acid, methyl ester (8CI) (CA INDEX NAME)



RN 29970-50-1 CAPLUS  
CN Thieno[3,2-f]quinoline-9-carbonitrile (8CI) (CA INDEX NAME)




RN 29970-51-2 CAPLUS  
CN Thieno[3,2-f]quinoline-7-carboxylic acid (8CI) (CA INDEX NAME)



IT 233-03-4  
RL: RCT (Reactant); RACT (Reactant or reagent)

10080926

(substitution reactions of)  
RN 233-03-4 CAPLUS  
CN Thieno[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)



L16 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2003 ACS  
AN 1962:38406 CAPLUS

DN 56:38406

OREF 56:7266a-h

TI Synthesis of 4,6-diaminoquinoline derivatives. I. Synthesis of pyrrolo[f]quinoline derivatives

AU Yoshikawa, Toshiyoshi

CS Univ. Kumamoto

SO Yakugaku Zasshi (1961), 81, 1317-22

CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Unavailable


AB 3,4-Br(H2N)C9H5N (4.5 g.) in 30 ml. concd. H<sub>2</sub>SO<sub>4</sub> at 0-3.degree. treated dropwise with a mixt. of 1.47 ml. HNO<sub>3</sub> (d. 1.42) and 10 ml. concd. H<sub>2</sub>SO<sub>4</sub>, stirred 1 hr., the product poured on ice, made alk. with Na<sub>2</sub>CO<sub>3</sub>, and the ppt. recrystd. (Me<sub>2</sub>CO) gave 62% 2,4,6-Br(H2N)(O<sub>2</sub>N)C9H4N (I), m. 289.degree.. Catalytic redn. of I in EtOH acidified with HCl (Pd-C) gave 96% 4,6-(H2N)C9H5N.2HCl, (II), needles, m. 319-20.degree. (decompn.). II (0.5 g.) in 0.8 ml. concd. HCl and 1 g. ice below 0.degree. treated dropwise with 0.17 g. NaNO<sub>2</sub> in 10 ml. H<sub>2</sub>O at 5.degree., the diazonium salt soln. poured into 1.31 g. Na<sub>2</sub>SO<sub>3</sub> in 10 ml. H<sub>2</sub>O at 0.degree., kept at 20.degree., dild. with 2 vols. H<sub>2</sub>O, acidified with HCl, heated 4 hrs. at 60-70.degree., cooled, equal vol. of concd. HCl added, the ppt. filtered off, taken up in a small amt. of H<sub>2</sub>O, filtered with C, and the filtrate treated with a small amt. of EtOH and satd. with HCl gas at 0.degree. gave 0.51 g. 4,6-H2N(H2NNH)C9H5N.2HCl (III), needles, m. 302.degree. (decompn.). III (0.15 g.) in H<sub>2</sub>O treated with PhCHO in EtOH and the ppt. filtered off gave 44% 4,6-H2N(R:NNH)C9H5N (IV) (R = PhCH), needles, m. 104.degree.. A mixt. of 0.1 g. III, 0.15 g. AcONa.3H<sub>2</sub>O, and 0.06 g. vanillin in EtOH reacted at room temp. to give 38% IV [R = 3,4-MeO(HO)C6H3CH], plates, m. 106.degree. (decompn.) (EtOH). Reaction of 0.2 g. III, 0.15 g. AcCO<sub>2</sub>H, and 0.4 g. AcONa.3H<sub>2</sub>O at room temp. and addn. of 1 ml. concd. HCl gave IV [R = Me(HO<sub>2</sub>C)C] as the HCl salt, m. 229-30.degree. (decompn.). III (0.5 g.) in Me<sub>2</sub>CO and 0.56 g. AcONa.3H<sub>2</sub>O refluxed 30 min., Me<sub>2</sub>CO removed, the residue made alk. with K<sub>2</sub>CO<sub>3</sub>, and the ppt. washed with EtOH gave 0.5 g. IV (R = Me<sub>2</sub>C) (V). m. 198.degree.. III (0.3 g.) in H<sub>2</sub>O, 0.15 g. PhCOMe in EtOH, and 0.3 g. AcONa.3H<sub>2</sub>O refluxed 1.5 hrs. gave 0.2 g. IV (R = PhMeC), needles, m. 178.degree.. A mixt. of 0.5 g. V, 1 g. ZnCl<sub>2</sub>, and 3 ml. p-cymene refluxed 2.5 hrs. at 200-10.degree. in N, the p-cymene decanted, and the residue extd. with abs. EtOH gave 29% 2-methyl-9-amino-3H-pyrrolo[3,2-f]quinoline (VI). ZnCl<sub>2</sub>, needles, m. 117.degree.. VI.ZnCl<sub>2</sub> (0.13 g.) in 25% KOH refluxed, the soln. concd., and the residue crystd. (EtOH) gave 81% VI, m. 105.degree. (decompn.). 6-(Me<sub>2</sub>C:NNH)C9H6N (1 g.), 2 g. ZnCl<sub>2</sub>, and 6 ml. p-cymene heated 2.5 hrs. at 175-80.degree. and concd. gave 0.6 g. ppt., m. 175-8.degree.; this extd. with CHCl<sub>3</sub>, and filtered with C, and the filtrate chromatographed (Al<sub>2</sub>O<sub>3</sub>) gave 36% 2-methyl-3H-pyrrolo[3,2-f]quinoline (VII), m. 198.degree. (C<sub>6</sub>H<sub>6</sub>); the CHCl<sub>3</sub>-insol. residue extd. with EtOH gave VII.ZnCl<sub>2</sub>, m. 267.degree.. IV (R = PhMeC) (0.2 g.), 0.5 g. ZnCl<sub>2</sub>, and 2 ml. p-cymene heated 2.5 hrs. at 190-200.degree. and the product treated as above gave 37% 2-phenyl-9-amino-3H-pyrrolo[3,2-f]quinoline-2H<sub>2</sub>O, needles, m. 110.degree. (Me<sub>2</sub>CO-Et<sub>2</sub>O). III (0.41 g.), 0.02 g. cyclohexanone in EtOH, and 0.03 g. AcONa.3H<sub>2</sub>O refluxed 50 min., the soln. made alk. with concd. NH<sub>4</sub>OH, the oily portion taken up in AcOH, heated 10 min. at 75-80.degree. with 2 drops concd. H<sub>2</sub>SO<sub>4</sub>, and the soln. poured into ice H<sub>2</sub>O gave 1-amino-8,9,10,11-tetrahydro-7H-pyrido[2,3-c]carbazole-0.5H<sub>2</sub>SO<sub>4</sub>.H<sub>2</sub>O, prisms, m. 345.degree. (decompn.) (MeOH).

IT 232-85-9, 3H-Pyrrolo[3,2-f]quinoline  
(derivs.)

RN 232-85-9 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)


10080926



IT 95196-74-0, 3H-Pyrrolo[3,2-f]quinoline, 9-amino-2-methyl-  
96418-17-6, 3H-Pyrrolo[3,2-f]quinoline, 2-methyl-  
97789-00-9, 3H-Pyrrolo[3,2-f]quinoline, 9-amino-2-phenyl-  
(prepn. of)

RN 95196-74-0 CAPLUS


CN 3H-Pyrrolo[3,2-f]quinoline, 9-amino-2-methyl- (7CI) (CA INDEX NAME)



✓

RN 96418-17-6, CAPLUS


CN 3H-Pyrrolo[3,2-f]quinoline, 2-methyl- (7CI) (CA INDEX NAME)



✓

RN 97789-00-9 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline, 9-amino-2-phenyl- (7CI) (CA INDEX NAME)



✓

L16 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2003 ACS

AN 1948:32069 CAPLUS

DN 42:32069

OREF 42:6823g-i,6824a-c

TI The constitution of calycanthines. II. Synthesis and absorption spectra of the compound C12H10N2

AU Eiter, K.

CS Univ. Vienna

SO Monatsh. (1948), 79, 17-21

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB Pure 2-carboline (VI), m. 215.degree. (0.2 g.), 0.0274 g. Na, and 3 cc. freshly distd. ClOH7Me (VII) were heated 5 hrs. in an open tube at 200-10.degree., 0.5 cc. MeI added, the tube sealed and heated overnight at 100.degree., VII removed in vacuo, and the residue distd. to give at 140.degree. a yellow oil (VIII) which crystd. VIII on refractionation gave 0.1175 g. N-methyl-2-carboline (IX), a blue fluorescing oil distg. at 110-30.degree., m. 53.degree. (from Et2O-petr. ether). IX, also prep'd. by heating 0.156 g. VI and 0.5 cc. MeI in a sealed tube 12 hrs. at 100.degree. (yield, 0.019 g.), was a pale yellow oil distg. at 90-100.degree.; picrate, yellow needles, m. 225.degree. (decompr.) (from alc.). 4-Carboline (X), m. 225.degree. (0.2 g.), 0.0274 g. Na, and freshly distd. VII treated as above with 0.5 cc. MeI gave 50 mg. N-methyl-4-carboline (XI), colorless oil, distg. at 130-50.degree., m. 88.degree.. From 0.1 g. X and MeI as above was obtained 0.021 g. XI;

10080926


picrate, needles, m. 261.degree. (decompn.) (from EtOH). IV was shown by mixed m.p. not to be IX or XI. The absorption curve of IV in dioxane showed 2 max. at 306 and 242 m.mu., and some similarity to the curves of pyrroquinolines (C.A. 33, 8202.1). For spectral comparison 2 unsuccessful attempts were made to prep. N-methylpyrroquinoline (XII); pyrroquinolinecarboxylic acid fused with ZnCl<sub>2</sub> gave the free pyrroquinoline (XIII) but treatment of XIII with (1) Na or K in VII, followed by MeI, or (2) MeI at high temp. gave no XII. The reaction of XIII with H<sub>2</sub>CO and HCO<sub>2</sub>H was also unsuccessful. The authors propose XIV and XV as possible structures of IV.

IT 232-85-9, 3H-Pyrrolo[3,2-f]quinoline

(prepn. of)

RN 232-85-9 CAPLUS

CN 3H-Pyrrolo[3,2-f]quinoline (8CI, 9CI) (CA INDEX NAME)



*Chem. letter*